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ABSTRACT 
 
Translating electrochemical aptamer-based sensors to real-world applications 
 
by 
 
Jacob Somerson 
 
By coupling the specific and selective binding of biomolecules with conformation-linked 
signaling and electrochemical outputs, electrochemical aptamer-based sensors (E-AB 
sensors) provide a unique ability to measure molecules in real-time directly in complex 
media. Because E-AB sensors do not require washing steps or reagent additions, they open 
the door for measurements directly where they are needed – in complex sample streams such 
as foodstuffs, clinical samples, and even directly within the living body. To further advance 
this promising technology, my work has addressed both improvements in the physical sensor 
and improvements in how we use the electron transfer kinetics underlying the signaling in 
these sensors to circumvent the drift associated with performing measurements directly in 
complex media. That is, using new electrode formats and new analytical signal-processing 
techniques, my thesis work created fully realized devices capable of measuring specific 
molecular targets in real time in relevant, highly complex sample streams. As examples, in 
my thesis I describe sensors supporting the measurement of a mycotoxin directly within the 
flowing sample stream of a foodstuff affected by that mycotoxin, the measurement of a 
malaria diagnostic protein in clinically-relevant ranges directly in a fingerprick-sized sample 
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of human serum, a new technique to measure a protein of interest directly in unprocessed 
whole blood – without pre-calibration, and new deployments of thin, surgically-implanted 
wire electrodes with sensors that measure, for the first time, in vivo blood concentrations in 
real time of a variety of small-molecule drugs as well as an arbitrary circulating protein of 
interest.  
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I. Introduction 
“The problem” 
Current methods for measuring specific molecules are, by and large, cumbersome, slow 
laboratory-bound processes. The availability of technologies that could measure arbitrary 
molecules rapidly and directly at the point-of-use or, ultimately, could monitor them in real-
time in a flowing sample stream could revolutionize healthcare, improve food safety, and 
enhance the efficiency of many industrial processes.  
The case for improved molecular measurements is amply illustrated in medicine, where 
sufficiently sensitive and inexpensive point-of-care testing promises to transform the field by 
further personalizing diagnosis, monitoring and treatment of infectious disease, chronic 
conditions and other indicators of health status. While outcomes vary wildly depending on a 
dizzying array of variables present in the intersection of human biology and medical 
infrastructure, point-of-care testing may reduce the length of hospital stays, ameliorate 
emergency department crowding and reduce time to clinical intervention [1–4]. Point-of-care 
testing is as effective in ensuring patient medication adherence as testing at a centralized 
pathology laboratory, and patients report higher satisfaction and a better relationship with 
their physician when their physician has immediate point-of-care results [5]. These 
measurements to improve patient adherence tend generally to be highly cost-effective if not 
cost-saving, with nonadherence costing the US $100 billion in avoidable healthcare costs 
[6]. In the developing world, point-of-care diagnostics improve linkage to care, reducing 
mortality and improving patient outcomes [7–9].  
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A. Current approaches to clinical point-of-use measurements 
Molecular measurements play a role in a wide range of applications, including clinical 
diagnostics, of course, but also wide manufacturing, environmental monitoring, and defense. 
To illustrate the gap between where current point-of-use measurement techniques are and 
where they aspire to be it is necessary to understand the state of the field as it exists today. 
To that end, I will examine the relatively well-developed market for point-of-care clinical 
diagnostics before discussing, in less detail, applications outside of the clinic. 
To date, point-of-use medical measurement approaches (e.g., home use or point-of-care) 
devices range from the simple, hand-held “dipstick” lateral flow immunoassay [10] to 
complex benchtop devices which miniaturize and automate multiplexed chemistry assays 
[11]. Of course, no device is perfect for all use cases and all settings, but there are general 
rules developed by the World Health Organization which have become benchmarks for 
point-of-use devices as a class [12]. A point-of-use device must be affordable, which can 
mean different things to different users. Generally, point-of-care medical devices look at the 
cost per quality-adjusted life year, a measure of life expectancy weighted to reflect the 
quality of life during those years [13]. Point-of-use devices must be accessible to end users 
which includes physical delivery of a device to the location where it is needed, ability for 
any (preferably minimal) equipment to operate within the degree of infrastructure where it is 
needed and ability for the test to be performed and understood by the person performing it. A 
point-of-use device must also be a good sensor: it must be sensitive, specific, rapid and 
robust. Of note, a point-of-use device may be less sensitive than a typical laboratory 
instrument but still provide results: a moderately-sensitive clinical test that gives immediate 
results improves outcomes just as much as a much-more-sensitive clinical test that requires a 
10-14 day waiting period between testing and action [14].  
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Ideally, these criteria make these devices relevant for multiple use cases along a range of 
infrastructure and budget levels. Nayak and coworkers describe four major medical use 
cases: moderate budget and a clinic infrastructure (e.g., ICUs, military base clinics), 
moderate budget and a field infrastructure (e.g. consumer devices, ambulance/EMS 
services), a constrained budget with clinic infrastructure (e.g. primary care clinics, NGO 
health centers) and a constrained budget with field infrastructure (e.g. global health, self 
testing) [15]. While the field of these devices is always expanding, I will aim to describe the 
major technologies driving commercially-available point-of-care devices: lateral flow 
immunoassays, strip technology with handheld readers, microfluidic cartridge-based devices, 
miniaturized flow cytometers, blood gas analyzers and miniaturized, automated clinical 
chemistry instruments [16]. 
Lateral flow immunoassays describe a broad class of qualitative (or semi-quantitative) 
single-use point-of-care sensors, best known as the underlying technology of the home 
pregnancy test [17]. These are typically presented as a strip or a card impregnated with 
multiple bio-recognition elements. The liquid sample of interest is applied to a pad on one 
end of the device and is wicked through a pad containing labeled recognition elements – 
typically antibodies [18], though assays have been described using nucleic acid recognition 
elements to measure DNA-DNA interactions [19] or nucleic acid aptamers [20]. The sample 
of interest and these recognition elements interact as the liquid flows through a membrane 
strip. The complex of the labeled recognition element and the target of interest are captured 
by another recognition element immobilized on a test line, giving a visible line in the 
presence of target [21]. Multiple test lines may be used to test for multiple targets [22] or the 
same target with varying affinity, giving semi-quantitative measurement [23]. These point-
of-care sensors are broadly applicable to a range of markers for infections, metabolic 
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disorders, toxic compounds, vaccination confirmation, contamination and pregnancy [17]. 
However, they are single-use and semi-quantitative at best. 
Handheld readers allow strip-based testing to add complexity and automation, reducing 
user error and enabling quantitative measurement of results. The most commonly-used (and 
most highly-developed) handheld meter – test strip device is the portable blood glucose 
sensor [24]. These sensors draw a ~1 µL volume of blood from a shallow finger-stick 
through a strip containing a specific enzyme that recognizes glucose, its coenzymes, an 
electrochemical mediator and a measurement electrode or a color-changing indicator 
molecule. The enzyme oxidizes glucose and electrons from the glucose are transferred to an 
electrochemical mediator. This molecule either delivers the electrons to an electrode for an 
electrochemical measurement or to a color-changing indicator for photometric measurement 
[25]. Handheld meters contain machinery for a simple electrochemical or photometric 
measurement, a timer for accurate sample measurement and internal calibration controls 
[26]. These systems provide simple, accurate quantitative measurements of blood glucose 
[27] but are of course dependent on the central sensor molecule: a naturally-occurring 
enzyme capable of converting blood glucose to an electrical signal. Efforts to expand this 
sort of detection have focused on coupling these handheld readers with microfluidic chips 
[28–32]. This enables the use of simple colorimetric, fluorescent and electrochemical 
devices to measure a readout of more-complicated chemistry to give quantitative results, 
though as of yet, only a few devices are FDA approved and large-scale microfluidics 
manufacturing is a challenge [33]. 
Another direction to move clinical measurement to the point of care is the miniaturized, 
automated instrument. Companies have commercialized automated clinical chemistry 
analyzers, blood gas analyzers and miniature flow cytometers to provide these technologies 
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to doctors’ offices, resource-poor regions or areas without trained lab personnel. As a 
general rule, the defining characteristic of these instruments is the move towards automation 
of all of the analytical and sample-processing steps required and removing all steps which 
may be sources of operator error [34]. Because these are often designed for clinicians with 
little training in laboratory quality practices, these instruments often include internal quality 
controls [35]. Bringing these instruments out of the laboratory and closer to the patient can 
provide faster turn-around times which can expedite therapeutic interventions [36]. 
Benchtop clinical chemistry analyzers cover a broad range of clinical chemistries from 
simple panels of blood chemistry (e.g., enzymes, substrates, lipids, electrolytes) [37] to 
measurements of blood gases and coagulopathy [38] to specialized panels for specific patient 
presentations (e.g., point-of-care cardiac troponin sensors for patients with acute chest pain) 
[39]. The need to count CD4 T-cells in HIV patients drove the miniaturization of the flow 
cytometer into a benchtop-sized analyzer [40]. 
Beyond the clinic, point of use technologies provide critical information regarding food 
taint, environmental monitoring, workplace safety assessments, air and water quality testing 
are a few among the many applications for which the need for rapid, decentralized 
information is more pressing than the absolute accuracy of the measurement. As most food 
quality measurements are commercialized, proprietary technologies, published articles are 
much more rare than clinical devices. That said, the range of commercial devices for 
decentralized food monitoring include analysis of bacterial and fungal food taint, food 
quality deterioration, allergen content and other food contents [41]. 
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B. Continuous monitoring 
While the range of point-of-use molecular detection technologies provide valuable 
information at the bedside or other areas with limited infrastructure, there are no general 
approach to date that can provide continuous, quantitative measurement directly in a 
complicated sample stream (including in vivo) against an arbitrary target of interest. An 
example of a particularly promising clinical application is use in therapeutic drug 
monitoring. Therapeutic drug monitoring is recommended in cases of pharmacokinetic 
variability, drug interactions, diseases with poor prognosis or for patient populations with 
significant underlying immunological conditions [42], but current techniques for drug 
monitoring are traumatic for the patient , complicated or expensive to perform. Typical drug 
monitoring requires up to a dozen individual blood draws timed precisely over twenty-four 
hours [43] and can be expensive and time-consuming to measure [44]. Even in best 
circumstances, the ex vivo measurement necessitates that all meaningful information will not 
be processed until after dosing. Promising drugs are often not prescribed because of the 
difficulty of monitoring individual patients for adverse events linked to their 
pharmacokinetics [42]. Similar challenges exist for monitoring the outputs of food 
production [45] and pharmaceutical manufacturing [46]. Given the still pressing need for 
continuous, quantitative sensing which can work directly in complicated sample streams, in 
my thesis work I aim to translate the electrochemical aptamer-based sensor, a technology 
with roughly fifteen years of benchtop use, into complex sample streams, including 
foodstuffs, clinical media and direct in vivo measurements in the bloodstream of a living 
animal. 
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C. The approach 
To create a synthetic sensor that is a) single step and reversible (thus ensuring ease of use 
and, ultimately, continuous monitoring) and b) performs well even in complex 
environments, my research turns to biological inspiration. That is, predicated by the 
argument that evolution has solved the problem of molecular sensing in complex 
environments (your body contains hundreds of receptors responding quantitatively to a 
myriad of specific small molecule and protein cues), my research program set out to engineer 
synthetic biomolecules to undergo similar robust measurement in complex media. To 
achieve this, I exploited two key elements of the chemoperception systems that nature 
employs: biomolecular recognition, and conformation-linked signaling. 
Engineering biomolecular recognition against arbitrary targets 
Biomolecular nanomachines successfully perform continuous monitoring and translation 
of binding events into biological response in incredibly complex intracellular environments 
and directly in the bloodstream. The most abundant biological recognition approach, protein 
recognition uses a large available chemical space (the twenty available functional groups of 
the twenty canonical amino acids plus the range of post-translational modifications) and 
millions of years of natural selection to create molecules which can sensitively recognize a 
target of interest with high specificity (recognizing the target over its similar analogues) and 
high selectivity (recognizing the target in a complex, crowded sample medium). Groups 
have tried to re-engineer proteins towards a new function of interest and though there have 
been advances in protein engineering towards adapting their specific recognition to a target 
of interest, we are still far from being able to generate synthetic proteins with specific 
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desired functions [47,48]. To mimic the biological functions of proteins in a more tractable 
molecule, we instead choose to engineer nucleic acids towards our desired functions.  
We use a biomolecule with a similarly large sequence diversity but significantly more 
predictable structure in our attempts to engineer novel synthetic biological recognition 
elements. To exploit the sensitivity, specificity and selectivity of biological recognition, we 
use deoxyribonucleic acid (DNA) as a powerful bioengineering building block. Though 
DNA has the biological function of coding the genetic instructions of an organism, its ease 
of synthesis and replication, chemical and physical stability, information density and 
structural predictability present a range of novel applications. Synthetic DNA is cheap to 
produce (cents per base) [49,50] and easy to replicate, as is required by its biological role 
[51,52]. DNA is physically and chemically stable unless exposed to strong oxidizing agents, 
low pH or nucleases, enzymes specifically evolved to degrade DNA [53]. The four distinct 
bases making up each position of this polymer chain enable a massive amount of 
information density: N4 possible sequences for a chain N bases long. This massive 
information density combined with the structural predictability of DNA base-pairing [54] 
enable the synthesis of molecularly encoded shapes [55] and even functional devices 
[56,57]. Other groups have used the massive sequence space of DNA molecules to barcode 
small molecules and short peptides for simple analysis and separation of large-scale 
chemical library spaces [53]. We use the large sequence diversity of DNA to find specific 
biorecognition of a target of interest by selectively enriching a very large pool of (semi-) 
random DNA sequences.  
Artificial selection applied to a large, randomized pool of nucleic acid sequences can 
create sensitive, specific and selective biological recognition between an arbitrary molecule 
and a specific, selected sequence known as an aptamer. Aptamers exploit the ease of 
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artificial DNA synthesis to create a large, random pool of DNA sequences, isolate the small 
fraction of sequences which bind to an arbitrary target of interest and replicate those 
sequences for either more stringent rounds of selection or further characterization of the 
selected sequence. Since Tuerk and Gold [58] and Ellington and Szostak [59] first described 
this method in 1990, aptamers have been reported to bind small molecule drugs, arbitrary 
proteins, heavy metals and full pathogen cells [60].  
Conformation-linked signaling: a strategy for measurement specificity 
Most biosensor approaches follow a two-step measurement strategy: a specific 
biomolecule binds its target followed by a second step to generate signal. For example, 
Enzyme-Linked ImmunoSorbent Assays (ELISAs) use highly specific antibody-antigen 
interactions to sensitively measure small amounts of clinical antigens, but their signal is 
linked to subsequent less-specific antibody recognition, and they thus require multiple 
washing steps to avoid false positives from nonspecific binding to the assay well [61]. 
Similarly, techniques like quartz crystal microbalance, surface plasmon resonance and 
electrochemical impedance measure use specific biochemical binding to measure small 
amounts of target, but their signal is linked not to the specific biochemical interaction [62–
64]. Rather, their signal is linked to change in the physical properties of the supporting 
surface and so they require extensive antifouling and washing treatments [65]. While these 
techniques perform well in a clean laboratory environment, bringing these technologies to 
areas with limited infrastructure or even to the patient bedside frustrates their selectivity. 
Biology, however, performs signal transduction directly within incredibly crowded, 
complex environments. Proteins transduce environmental cues into active signals reliably 
and repeatedly directly in circulating blood and living cells. A common strategy across 
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proteins is linking function directly to binding-induced conformational change. For example, 
the glucokinase protein catalyzes the physphorylation of glucose after being activated by a 
small molecule. Binding of the glucokinase activator to glucokinase stabilizes a 
conformational shift which properly orients the catalytic residues of the enzyme to the 
glucose binding pocket [66]. Similarly, G-protein coupled receptors use binding-induced 
conformational changes to physically transduce environmental cues from outside cells to 
trigger responses inside the cell [67]. To mimic this mechanism, we use structure-switching 
DNA sensors which directly transduce target binding into a conformational change which 
intrinsically changes the electronic signal from the attached electrochemical tag [68]. 
Electrochemical aptamer-based sensors 
Electrochemical aptamer-based sensors (E-AB sensors) combine artificially engineered 
biological recognition with selective, conformationally-linked signaling and analytic, 
quantitative electrochemical measurement to enable sensitive, selective measurements 
directly in complex media. By synthesizing a specific aptamer sequence modified with a 
thiol anchor and an electrochemically-active redox tag, we create biosensor molecules which 
bind with near-covalent strength to a gold electrode and translate the binding of their target 
of interest to a quantitative change in the electrical signal from the redox tag. This approach 
uses the selectivity of electrochemical measurement to complement the specificity of 
biochemical binding; electrochemical voltammetry measures only the current at a specific, 
narrow electrochemical potential. The narrow measurement window minimizes the number 
of potential species which may interfere with the sensor signal, enabling measurements 
directly in complex samples which obstruct fluorescent or colorimetric biosensors. 
Electrochemical measurement also enables rapid, robust, repeated measurements of the same 
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molecule in quick succession, allowing for continuous, long-term measurement. Because 
these sensors can operate directly in their complex medium of interest without preprocessing 
or washing, this opens the door for continuous biosensing of a target of interest directly in a 
complex sample stream.  
 
Previous work in our group began to demonstrate the ability of E-AB sensors and their 
analogues, E-DNA sensors (DNA-based electrochemical sensors which recognize 
complementary strands of DNA), to find their targets in dirty, somewhat complex samples. 
Lubin et al. demonstrated single measurements of DNA-DNA interactions directly in blood 
serum, urine, saliva, mud and Guinness beer [69]. Cash et al. devised a general strategy for 
using electrochemical DNA-based sensors to take single measurements of antibody 
concentrations in blood serum and White et al. created a platform to measure six specific 
antibodies of interest in blood serum [70,71]. Swensen et al. performed the first continuous 
measurement in complex media, measuring changes in cocaine concentration for just over an 
hour in blood serum flowing through a microfluidic device [72]. However, further 
challenges remained in translating these biosensors to implantation within the bloodstream 
of a living animal or continuous measurements in whole, unprocessed blood or even 
expanding the repertoire of molecular measurement directly within the medium present at 
the point-of-use. 
In the next few chapters, I will demonstrate the translation of these electrochemical 
aptamer-based sensors off of the benchtop and directly into the complex environments where 
they can provide uniquely continuous quantitative measurements. I demonstrate the use of 
these sensors as measurements of food safety by measuring a mycotoxin directly in coffee 
and melamine directly in milk, rapid reagent-free measurements of arbitrary protein 
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biomarkers directly in clinical media, continuous quantitative measurements of arbitrary 
small-molecule drugs directly in the bloodstream of a living animal and continuous 
monitoring for arbitrary protein spikes directly in the blood of a living animal. 
 
D. My contribution 
Two major challenges to moving E-AB sensors from the benchtop into the point-of-use 
(including direct in vivo implantation) are the design of an electrode well-suited to the 
environmental conditions where it will be used and overcoming the nonspecific signal drift 
observed in particularly complex samples. 
 
Figure 1.1. Development of an electrode for deployment directly in the jugular vein of a 
living rat. (A) Early electrode prototypes consisted of a thick gold wire to be surgically 
inserted directly into the jugular vein of a rat. (B) An early attempt to prevent venous 
collapse protected the wire electrode and a combination counter/reference electrode within a 
crude stent made from a short length of flexible tubing. (C) Another electrode prototype 
protected a gold wire electrode with a short length of microdialysis tubing and delivered 
both the working electrode and a combination counter/reference electrode within a standard 
18 gauge catheter. A variation of this electrode (without the microdialysis tubing and 
catheter) is used for in vitro PDGF-BB detection in Chapter IV. 
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A substantial portion of moving a sensor from the benchtop to the point-of-use is the 
physical engineering of an electrode which can survive the environment where 
measurements take place. The development of an electrode for surgical implantation into the 
jugular vein of a rat proved a challenge – even with expert surgeries, early experiments were 
plagued with collapsing veins following surgical implantation. The development of a sensor 
which could be inserted with minimal invasiveness and that did not occlude bloodflow 
required multiple generations of electrode development. Early electrode generations, shown 
in Figure 1.1, attempted to combine a working electrode (modified with our E-AB sensor) 
and a counter/reference electrode (required for voltammetric measurement) in a minimal 
package which would ensure delivery of fresh bloodflow over the sensor surface.  
 
Figure 1.2. Our successful electrode design packages a microdialysis-membrane-protected 
gold working electrode and a counter/reference electrode within an 18 gauge catheter. 
Crucially, slits are cut into the catheter to encourage bloodflow over the electrode surface 
and a tube is inserted into the top of the catheter to allow pressure exchange following 
surgical implantation. (Patent application filed, UC Case 2016-135-0) 
 
Our final electrode design, used for the in vivo studies in Chapters V and VI, maintains 
the microdialysis-membrane-protected working electrode and the small counter/reference 
electrode packaged in an 18 gauge surgical catheter (Fig. 1.2). This new design, however, 
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includes a mechanism to equalize pressure within the catheter following implantation and 
slits in the catheter to encourage bloodflow over the electrode surface. This electrode, 
developed from the prototypes in Fig. 1.1 with the help of Netz Arroyo-Currás, has a patent 
application filed under UC Case 2016-135-0. 
 
Another large component of my work relies on using the kinetic information measured 
with square wave voltammetry, a kinetically-sensitive electrochemical technique. This 
expands on work from White et al. examining the kinetic dependence of the electric signal 
generated by our sensors [73]. Briefly, square wave voltammetry uses short potential pulses 
and differential measurement to precisely measure the faradaic current generated by 
oxidation and reduction of a redox-active molecule and not the capacitive charging current at 
the electrode surface [74]. We understand the amount of current to be related to the 
equilibrium probability of the redox tag interacting with the electrode surface in a manner 
that supports electron transfer, which is intrinsically linked to the overall flexibility of the 
DNA construct [75]. (Though, of course, there is not a consensus on the mechanism of 
electron transfer [76,77], this model proves sufficient to explain and predict the phenomena 
observed in sensor signal.) The binding of a target to an E-AB sensor changes the observed 
flexibility of the E-AB construct, which results in a measurable shift in the electron transfer 
kinetics between the redox tag and the electrode surface [73]. By measuring one population 
of molecules at different timescales, we are able to deconvolute the specific target-binding 
signal from the nonspecific signal drift that may occur in particularly complex clinical 
media. 
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Figure 1.3. Rather than (A) the model assumed from FRET and fluorophore-quencher 
studies where target binding (red oval) changes the E-AB probe from an unbound state 
which does not exchange electrons with the electrode surface (left) to a bound state which 
does exchange electrons with the electrode surface (right), E-AB sensors are better 
understood as two populations with distinct kinetics (B). The unbound state can explore a 
larger conformational space, with a relatively low equilibrium probability of the redox tag 
(blue hexagon) exchanging electrons with the electrode surface. The bound state is more 
tightly constrained, holding the redox tag closer to the electrode surface and speeding up 
electron transfer. (C) Plotting peak currents against the square wave pulse width shows that 
binding of a target, here 3 µM of doxorubicin, increases the overall speed of electron 
transfer. This allows us to measure multiple regimes of sensor signal. 
 
By modifying the timescale of our square wave measurement, we are able to explore 
multiple signaling regimes of the same population of molecules. Figure 1.3 shows the 
kinetic model of our sensors in their unbound and bound states (Fig. 1.3B) and the 
kinetically-dependent currents observed in bound and unbound states (Fig. 1.3C). When 
measuring at higher frequencies, the faster electron transfer between the tightly-constrained 
bound sensor and the electrode surface dominate, so current increases upon binding. When 
measuring at lower frequencies, the faster electron transfer from the tightly-constrained 
bound sensor is depleted by the end of the pre-measurement pulse, and so the slower 
electron transfer from the unbound, loosely-constrained sensor molecule dominates, so 
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current decreases upon binding. There is also a crossover point where the electron transfer 
rates between the bound and unbound states are balanced, this creates a non-responsive 
measurement frequency insensitive to target binding. 
By using measurement frequencies from multiple regimes, we can create a self-
calibrating reading to separate the non-specific signal drift from the specific target-derived 
signal. This is described in more detail in Chapters IV, V and VI. Briefly, multiple parallel 
measurements at different frequencies are compared to create a stable sensor signal that 
responds only to target and rejects nonspecific drift. KDM, a technique first described by 
Ferguson et al. [78], finds two frequencies with similar drift and dissimilar signal response, 
normalizes each signal to some baseline, and subtracts the normalized signals from each 
other to create more stable measurement baselines. Using this technique and the electrode 
development earlier described, I measured target addition directly in whole unprocessed 
blood for this first time. This work further developed into the in vivo small molecule work 
described in Chapter V. 
“Calibration-free” measurement, a technique first described by Li et al. [79], uses the 
ratio between a signal-on frequency and a nonresponsive frequency to reproducibly measure 
concentrations in complex media as long as a reliable “training set” of electrodes in similar 
conditions can be used to create a reliable fit in advance. Ratiometric measurement, a 
technique first described in my work in Chapter VI, adds the robustness from KDM 
stabilization to the advantages of calibration-free measurement by calibrating a baseline 
reading directly in the medium of interest before measurement begins. This new ratiometric 
methodology produces in vivo continuous measurements with greater stability and 
reproducibility than other previously employed techniques. 
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II. Electrochemical Aptamer-Based Sensors for Rapid Point-of-Use 
Monitoring of the Mycotoxin Ochratoxin A Directly in a Food Stream1 
Abstract  
The ability to measure the concentration of specific small molecules continuously and in 
real time in complex sample streams would impact many areas of agriculture, food safety, 
and food production. Monitoring for mycotoxin taint in real time during food processing, for 
example, could improve public health. Towards this end, we describe here an inexpensive 
electrochemical DNA-based sensor that supports real-time monitor of the mycotoxin 
ochratoxin A in a flowing stream of foodstuffs. 
A. Introduction 
Mycotoxins, a broad class of small molecule natural products produced by molds, are 
toxic to humans and other vertebrates. They primarily arise in foods stored in damp 
conditions and outbreaks are typically reported in the developing world. For example, after a 
jaundice outbreak in the Eastern and Central Provinces of Kenya sickened 317 with 125 
deaths a survey of maize products in the region found more than half were contaminated 
with mycotoxin [1]. The specific mycotoxin ochratoxin A contaminates a wide range of 
crops worldwide, including coffee beans, grapes and many grains used both for human 
consumption and animal feed. It is primarily a nephrotoxin, but animal studies also show 
that it has liver toxicity, immune suppression, teratogenic and carcinogenic activity [2]. 
                                                 
1 This chapter is published as J. Somerson and K.W. Plaxco, “Electrochemical Aptamer-
Based Sensors for Rapid Point-of-Use Monitoring of the Mycotoxin Ochratoxin A Directly 
in a Food Stream”, Molecules 2018, 23(4), 912; doi:10.3390/molecules23040912 and is 
reproduced under creative commons open access. 
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Ochratoxin A contaminates a variety of crops worldwide with contaminating concentrations 
varying widely geographically and between crops [3]. Estimates of the tolerable human 
intake vary widely, as do regulatory limits of maximum acceptable concentration of 
ochratoxin A in human and animal foodstuffs [4]. The EU limits ochratoxin A 
concentrations on coffee beans to 5 µg/kg (roughly corresponding to 1 nM in brewed coffee) 
and ochratoxin A has been reported in concentrations as high as 1200 µg/kg (roughly 
corresponding to 200 nM in brewed coffee) [5,6].  
The ability to rapidly detect or, better still, continuously monitor for mycotoxin 
contamination would significantly improve the safety of our food supply. Current state of the 
art in mycotoxin detection, however, depends on cumbersome laboratory-based techniques, 
with the most common being high-performance liquid chromatography [7]. While these 
techniques are sensitive and accurate, they are often inaccessible or economically 
challenging to deploy in the developing world[8]. An inexpensive detector to measure a 
mycotoxin at the point of use or the point of production would make measurement 
accessible to the developing world and improve the ease of measurement in the developing 
world. In response, we have developed an electrochemical aptamer-based biosensor (E-AB 
sensor) for the detection of this mycotoxin.  
The ochratoxin A-detecting E-AB sensors, like all sensors in this class, employ an 
electrode-bound, target-recognizing DNA aptamer modified with an electroactive “redox 
reporter” (Fig. 2.1). Specific binding of the target alters the conformation of the aptamer, 
changing the efficiency of electron transfer between the reporter and the electrode. 
Interrogating this system using square wave voltammetry, an electrochemical measurement 
technique that is particularly sensitive to changes in transfer rates, we observe a change in 
measured current that is quantitatively related to the concentration of the target. 
  25 
Conveniently, such measurements are rapid, taking only seconds per measurement, and rely 
only on inexpensive equipment ranging from thousands of dollars for a research-grade 
instrument to under $100 for a simple, portable potentiostat [9]. Here we report an E-AB 
sensor for the detection of the mycotoxin ochratoxin A directly in flowing foodstuffs without 
the addition of any modifying reagents, allowing for the continuous monitoring of food 
processing workflows. 
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Figure 2.1. (A) The ochratoxin A-detecting E-AB sensor consists of an ochratoxin A-
binding DNA aptamer modified attached via its 5’ end to a gold electrode using a 6-carbon 
thiol linker (which forms part of a self-assembled monolayer) and modified on its 3’ end 
with a methylene blue redox reporter (blue circle, “MB”). The binding of ochratoxin A (red 
oval) alters the aptamer’s conformation, changing in turn the rate of electron transfer in a 
manner easily monitored using square wave voltammetry [10]. (B) At higher square wave 
frequencies square wave voltammetry is more sensitive to rapid electron transfer, and thus 
target addition increases the observed current. (C) At lower frequencies, in contrast, target 
addition decreases the observed current.  
 
B. Results and Discussion 
 To create an ochratoxin A-detecting E-AB sensor we have employed an aptamer 
previously shown to bind this target with good specificity and affinity[11]. To date, several 
other groups have employed this aptamer for mycotoxin detection [11–14]. All of these 
previously reported, ochratoxin-detecting “aptasensors,” however, either require reagent 
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additions or other processing steps, thus increasing complexity and precluding continuous, 
real-time monitoring, or are based on fluorescence measurements, which are cumbersome 
and difficult to perform in foodstuffs due to autofluoresence and often significant light 
absorption and scattering. E-AB sensors, in contrast, are small (millimeter-scale), are 
supported by inexpensive, hand-held electronics [9] and provide a reagentless, single-step 
approach to measurement directly in highly complex media (e.g. whole blood, cell lysates, 
and foodstuffs) [15–18] .  
In order to support their use in E-AB sensors and many other sensing approaches an 
aptamer must undergo a conformational change upon target binding. Previously published 
works with this ochratoxin A aptamer have achieved this by adding to the sample solution a 
short DNA strand complementary to part of the aptamer sequence [11–14]. This creates an 
equilibrium between the partially double-stranded conformation (aptamer plus complement) 
and the free, properly folded aptamer. Because only the properly folded aptamer binds the 
target, target binding drives this equilibrium to the aptamer fold, coupling recognition with a 
large change in conformation[19,20] . The thermodynamics of this equilibrium (which is 
defined by the number of self-complementary bases in the complex and the stability of the 
aptamer fold) modulates the sensor’s signal gain (relative signal change upon target binding) 
and its affinity, with higher gain but poorer affinity being associated with stronger 
hybridization to the complement. Further limiting this approach, the complement is a 
separate piece of DNA that is “lost” during use and must be replenished by the user before 
the sensor can be re-used. To overcome this limitation we instead coupled the complement 
to the aptamer sequence via an unstructured polythymine linker to create a single, self-
complementary strand that cannot be washed away in a flowing sample stream, for example. 
Specifically, we created two constructs: one with the 10-base complement used in the earlier 
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literature and a sensor with only 5 self-complementary bases (Fig. 2.2A). Characterizing 
these constructs, however, we saw little E-AB signaling (Fig. 2.2B). Ironically, however, we 
found that the parent aptamer already produces acceptable E-AB signal gain without the 
addition of any complementary sequence, presumably because it undergoes a binding-
induced conformational change without requiring displacement of a complement. 
Specifically, we observe a 12% signal increase upon addition of saturating target to this 
sensor when it is interrogated at a square wave frequency of 240 Hz, and a “signal-off” a 
13% signal decrease when interrogated at 20 Hz (Fig. 2.3). 
 
Figure 2.2. (A) To identify the E-AB sensor with the highest gain we explored the simplest 
linear aptamer sequence and two variants to which we added self-complementary tails. (B) 
Constructs with 5 and 10 self-complementary bases added to the 3’ end of the aptamer 
(orange and light blue) do not, however, exhibit any significant change in signal upon target 
addition. An aptamer lacking any self-complementary tail (black), in contrast, exhibits the 
expected binding curve. Error bars shown are standard error of the mean for 4 (no tail) or 2 
(5 bp, 10 bp tail) independently fabricated sensors.  
 
The occurrence of both signal-on and signal-off behavior in the sensor provides an 
opportunity to employ Kinetic Differential Measurement (KDM), a method of improving the 
gain and drift stability of E-AB sensors [21]. KDM does so by measuring two regimes of the 
electron transfer these sensors use as their signaling mechanism: a fast, “signal-on” regime 
where target addition increases electrochemical signal and a slow, “signal-off” regime where 
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target addition decreases electrochemical signal (Fig. 2.1). Taking the difference between 
these two measurements we improve the gain of the ochratoxin A-detecting sensor to 25%. 
The resultant sensor binds its target with a KD of 6.5±0.6 µM when challenged in phosphate 
buffered saline (Fig. 2.3A). It is also rapid, fully responding to the addition of 800 µM target 
within the few seconds it takes to perform the requisite (two per time point) square wave 
voltammetric scans (Fig. 2.3B). 
 
Figure 2.3. (A) The ochratoxin A-detecting sensor responds quantitatively to its target with 
a KD of 6.5±0.6 µM in, as shown here, a simple buffer sample. Kinetic Differential 
Measurement (KDM), which takes the difference between measurements obtained at signal-
on and signal-off square wave frequencies allows us to improve signal magnitude and self-
correction for more stable signal [21]. Error bars shown for the 20 Hz and 240 Hz data are 
the standard deviation of 4 replicate electrodes. Error bars shown for KDM are the standard 
error of the mean for 4 replicate calculations. (B) The E-AB ochratoxin A sensor responds 
rapidly when challenged with target. Shown is the current of a single sensor interrogated 
multiple times in succession in buffer both before and after the sudden addition of saturating 
(800 µM) target. 
 
To achieve real utility as a point-of-care or point-of-production sensor a device must be 
selective enough to measure its target directly in the unfiltered, unadulterated media of 
interest, and be highly specific for that target. To illustrate the utility of our sensor for the 
measurement food taint in relevant foodstuffs, we thus challenge it in unprocessed iced 
coffee and find that our sensor is selective enough to work directly in this undiluted, 
unadulterated commercial food product (Fig. 2.4A). Under these conditions it exhibits a 
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signal gain of 33% and a KD of 19±2 µM. To demonstrate the value of our sensor in 
measuring only the target of interest, we also challenged it with five other mycotoxins and 
find that, as expected, our sensor responds only to the specific mycotoxin ochratoxin A (Fig. 
2.4B).  
 
 
Figure 2.4. The E-AB ochratoxin sensor is selective enough to work when challenged 
directly in a realistically complex sample matrix, and highly specific for its target. (A) 
Shown here, for example, are data collected in flowing, undiluted coffee. Error bars shown 
are standard error of the mean for 6 replicate electrodes. (B) The E- sensor is also highly 
specific for its target, ochratoxin A (O. A); it does not respond to the mycotoxins, Aflatoxin 
B1 (A. B1), Aflatoxin B2 (A. B2), Aflatoxin G1 (A. G1), Aflatoxin G2 (A. G2) or 
Fumonisin B1 (F. B1). Each bar represents the KDM signal gain of sensors in buffer 
challenged with 10 µM of mycotoxin, error bars reflect the standard error of the mean for 3 
replicate electrodes.  
 
The resulting E-AB sensor demonstrates a sensitive, specific, rapid single-step 
measurement of ochratoxin A concentrations directly within a relevant foodstuff. This 
enables point-of-care measurements in resource-limited areas, providing a fast, simple 
assurance against food taint. 
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C. Materials and Methods  
Materials. 
Ochratoxin A was purchased from Enzo Life Sciences (Farmingdale, NY) and used as 
received without further purification. Ochratoxin A was dissolved in ethanol to a 
concentration of 61.9 µM (25 mg/mL) then further diluted for titration in the same media as 
measurements were performed. Aflatoxin B1, aflatoxin B2, aflatoxin G1, aflatoxin G2 and 
fumonisin B1 were purchased from Sigma Aldrich (St. Louis, MO). 20X phosphate-buffered 
saline (PBS) was purchased from Sigma Aldrich (St. Louis, MO), diluted to 1X 
concentration and pH corrected to 7.4 using sodium hydroxide and hydrochloric acid. 
Starbucks brand Unsweetened Iced Coffee was purchased from Ralphs supermarket (Santa 
Barbara, CA) and used as received. Oligonucleotides were synthesized by Biosearch 
Technologies (Novato, CA) and purified by dual HPLC. 6-mercapto-1-hexanol and tris(2-
carboxyethyl)phosphine were purchased from Sigma Aldrich (St. Louis, MO) and used as 
received. 
Ochratoxin A aptamer sequences. 
Oligonucleotides were synthesized by Biosearch Technologies (Novato, CA) and 
purified by dual HPLC. All constructs had a 6-carbon thiol linker on the 5’ end and a 
methylene blue redox tag on the 3’ end. Self-complementary regions are shown underlined. 
0 complementary bp 
GATCG GGTGT GGGTG GCGTA AAGGG AGCAT CGGAC A 
5 complementary bp 
GATCG GGTGT GGGTG GCGTA AAGGG AGCAT CGGAC ATTTT TTGAT GC 
10 complementary bp 
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GATCG GGTGT GGGTG GCGTA AAGGG AGCAT CGGAC ATTTT TTTGT  
CCGAT GC 
 
Sensor preparation. 
Our biosensor consists of a 2 mm diameter gold disk electrode (CH Instruments, Austin 
TX) coated with a mixed self-assembled monolayer of thiol-modified DNA strands and 6-
mercapto-1-hexanol. Electrodes were physically polished and electrochemically cleaned as 
previously described [22]. DNA sequences were treated with a 1000-fold molar excess of 
tris(2-carboxyethyl)phosphine to reduce the 5’ disulfide modification to a free thiol. 
Following electrochemical cleaning, electrodes were immersed in 200 nM reduced DNA in 
1X PBS at room temperature for 1 h and then moved to 20 mM 6-mercapto-1-hexanol 
solution in 1X PBS at 4 °C overnight. 
 
Electrochemical measurements. 
Electrochemical measurements were performed at room temperature using a CHI630C 
potentiostat with a CHI684 multiplexer (CH Instruments, Austin, TX) and a standard-three 
electrode cell containing a platinum wire counter electrode and an Ag/AgCl reference 
electrode (both from CH Instruments, Austin, TX). Square wave voltammetry was 
performed at 240 Hz using a potential step of 0.004 V and at 20 Hz using a potential step of 
0.001 V, both using an amplitude of 0.025 V. All experiments were conducted in a closed-
loop system with a continuous flow of test media (~1 mL/s) using a circulator pump (Cole-
Parmer, Vernon Hills, IL).  
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III. An Electrochemical Sensor for Point-Of-Care Measurement of a 
Malaria Biomarker in Small Volume Clinical Samples2 
Abstract: 
The gold standard for the diagnosis of malaria, a disease that continues to affect 
hundreds of millions of people each year, is microscopic evaluation of a blood smear. Given 
that (i) this requires skilled operators and non-trivial clinical infrastructure, and that (ii) 
malaria predominantly strikes in resource-limited areas there remains a pressing need for 
improved methods of malaria diagnosis. To this end, the measurement of molecular markers 
of malaria appears a promising alternative means of diagnosing the disease, but to date these 
have been primarily deployed in “dipstick” assays. This gives only a qualitative yes-or-no 
answer and not quantitative information, which is linked to disease progression and severity. 
In response, we describe here an electrochemical DNA-based sensor that can perform the 
measurement of a diagnostically relevant malaria biomarker within five minutes using a 
finger-prick serum sample without requiring sample processing, wash steps, or operator 
interpretation. 
A. Introduction 
The World Health Organization Global Technical Strategy now aims for full elimination 
of the malaria parasite [1]. Despite significant recent progress, however, malaria still infects 
more than 200 million patients per year and kills hundreds of thousands [2]. In part this is 
because eradication of the disease will require diagnostic techniques that allow for rapid 
detection of the parasite, Plasmodium falciparum, in the resource-limited areas where 
                                                 
2 This chapter in preparation for publication as J. Somerson, J. Yu, J.P. Wang and K.W. 
Plaxco, “An electrochemical sensor for point-of-care measurement of a malaria biomarker in 
small volume clinical samples”. 
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malaria persists. Specifically, a key element of malaria eradication will be the identification 
of the reservoir of asymptomatic, subcritical infections that contribute to the spread of the 
disease, which will require point-of-care diagnostics suitable for measuring parasite load in 
asymptomatic low-level infections [3]. Unfortunately, however, the current gold standard for 
malaria diagnosis, the examination of a blood smear by microscopy, requires a stable 
infrastructure and a skilled microscopist [4]. The technique is thus complex enough that it is 
typically only performed on acute cases; it is far too cumbersome to employ for disease 
surveillance  
Motivated by the need for improved methods of malaria diagnosis significant effort has 
gone towards identifying molecular markers indicative of the infection [5]. Among the more 
promising of these is the histidine-rich protein 2 released by Plasmodium falciparum 
(HRP2). This 32.8 kDa, water-soluble protein correlates quantitatively to infection severity 
and the risk of mortality [6,7], rendering it an excellent biomarker for disease load. Moving 
the measurement of this protein from centralized laboratories to infected areas, however, 
proves challenging: while laboratory techniques exist to sensitively and specifically measure 
protein biomarkers, they are generally cumbersome, resource-intensive and expensive to 
operate. Protein measurement is further complicated by the complex clinical samples to be 
measured – human blood, for example, is a viscous, optically-dense fluid filled with 
proteins, cells, clotting factors and other potential interferents. Though recent developments 
in blood separation by microfluidic means [8] and clever techniques to reproduce clinical 
instruments in an inexpensive way such as the “paperfuge” [9] open the door for point-of-
care blood separation for serum measurement, even serum remains a challenging sample 
matric for most biosensor approaches [10].  
In contrast to most other proposed point-of-care molecular measurement technologies 
[11], electrochemical aptamer-based sensors (E-AB sensors) couple the specificity 
(recognizing a target over its similar analogues) of biomolecular recognition with the 
selectivity (recognizing a target in a complex, crowded sample medium) of conformation-
linked, electrochemical read-outs to quantitatively measure a target of interest directly within 
complex media like blood serum [11]. E-AB sensors use aptamers, short nucleic acid strands 
selected in vitro, to sensitively and specifically bind their targets, rendering the approach 
quite general [12]. The necessary aptamer is attached by one end to an interrogating 
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electrode and modified with an electrochemically-reporting redox moiety at its distal end. 
When the aptamer changes conformation upon target binding the resultant change in the 
sensor’s electrochemical output is quantitatively related to the concentration of the target 
[11]. Critically, because: i) binding-induced conformational changes are not mimicked by 
non-specific adsorption and ii) the electrochemical signal is limited to a narrow potential 
window over which there are few electrochemically-active interfering species, these sensors 
perform well even when challenged directly in complex media, including, for example, 
undiluted blood serum [13–15]. When this attribute is combined with the small size of E-AB 
sensors and the inexpensive electronics required to drive them [16], the platform appears 
well suited for point-of-care applications in resource-poor environments. Motivated by these 
observations we have developed here an electrochemical aptamer-based sensor capable of 
measuring circulating HRP2 within minutes directly in a small-volume serum sample at the 
point of care. 
 
B. Results and Discussion 
Our approach to the point-of-care diagnosis of malaria employs an E-AB sensor capable 
of measuring the HRP2 biomarker in a clinical sample (Fig. 3.1). To fabricate this we 
employed an aptamer previously selected to sensitively and specifically bind this target [17], 
which was truncated to destabilize it such that it undergoes binding-induced folding. 
Specifically, as the concentration of target increases, the population of target-bound 
aptamers increases, accelerating electron transfer (Fig. 3.1A) and producing a large signal 
increase when the sensor is interrogated using square wave voltammetry at a frequency of 
xxx Hz (Fig. 3.1B). Measuring over a range of HRP2 concentrations we observed the 
expected Langmuir isotherm relating signal response to target concentration (Figs. 3.2, 3.3). 
Specifically. When challenged in phosphate buffered saline the sensor exhibits a KD of 
~9000 ng/mL HRP2 and a 60% increase in electrochemical signal at saturation (Fig. 3.2).  
  38 
 
Figure 3.1. (A) The aptamer used in our E-AB sensor changes conformation upon binding to 
the HRP2 protein, which, in turn, improves the accessibility of the methylene blue 
electrochemical reporter to the electrode surface. This innately changes the rate of electron 
transfer, which is exhibited as a change in the peak current (B). (C) The versatile self-
assembly of our aptamer system allows us to use a variety of electrode formats; the chip used 
in this work allows us to measure in <10 µL sample volumes.  
 
To enhance signal gain and reduce sensor drift we employ Kinetic Differential 
Measurement (KDM) [18]. This technique takes advantage of the fact that square-wave 
voltammetry is extremely sensitive to changes in electron transfer rate; so much so that we 
can convert our sensor from being signal on (current increases upon binding) to signal off by 
altering the square wave frequency (Fig. 3.2). By taking the difference between these two 
normalized signals KDM increases the signal gain of our sensor. Using this approach we 
observe the expected Langmuir isotherm response to HRP2 with a signal change (signal 
gain) of ~70% at saturating target concentrations in phosphate buffered saline. 
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Figure 3.2: Measurement of HRP2 in flowing buffer on micro-scale electrodes in a small 
volume chip. Our sensors sensitively measure HRP2, a malaria diagnostic protein, in 1X 
PBS buffer with 1% added BSA. We use two measurement frequencies to improve signal 
gain and correct for in vitro drift from electrode fouling. 60 Hz (blue diamonds) is a “signal-
on” frequency and 10 Hz (orange squares) is a “signal-off” frequency. KDM (black 
triangles) is the subtractive difference between these two frequencies. Error bars represent 
the standard deviation of two electrodes. Sample medium is 1X PBS with 1% BSA. 
 
To achieve point-of-care clinical utility a technology must provide actionable results 
within the roughly twenty minute timeframe of the average outpatient doctor-patient 
interaction [19] and cannot require anything more cumbersome than a finger-prick blood 
sample. Towards this end, we have developed a sensor which can return a quantitative 
answer directly in a fingerprick-sized droplet of blood serum within minutes. Using our 
micro-electrodes in a small-volume chip (Fig. 3.1C) we measure in <10 µL of blood serum 
with no wash steps or reagent addition and we observe response with an equilibrium time 
constant of 1.0 ± 0.4 min-1 (95% confidence interval) (Fig. 3.3). In this low-volume device 
supporting rapid measurements, we observe the expected Langmuir isotherm response to 
HRP2 with a signal gain of ~50% at saturating target concentrations and a KD of ~9000 
ng/mL (Fig. 3.4), well within the clinically observed range between 1 and ~20000 ng/mL in 
patient serum [7].  
  40 
0%
50%
100%
0 5 10
Time (min)
S
ig
n
a
l 
c
h
a
n
g
e
 (
K
D
M
)
 
Figure 3.3. These sensors return actionable results within 5 minutes, allowing for immediate 
diagnosis and treatment within the same visit. Signal shown is KDM using the difference 
between 60 Hz and 10 Hz measurements. At the dashed line, 10000 ng/mL of HRP2 was 
spiked into the sample medium (1X PBS with 1% BSA). The equilibrium time constant for 
signal response is 1 ± 0.4 min-1 (95% confidence interval). Error bars shown are the standard 
deviation of 3 microelectrodes in a small-volume chip. 
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Figure 3.4. Measurement of HRP2 in vitro in bovine blood serum. Our sensors sensitively 
measure HRP2, a malaria diagnostic protein, directly in clinical samples. We use multiple 
measurement frequencies to improve signal gain and correct for in vitro drift from electrode 
fouling. Signal shown is KDM using the difference between 100 Hz and 40 Hz 
measurements. Error bars shown are the standard deviation of two microelectrodes. 
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Using this technology, we have demonstrated a point-of-care device for the rapid, 
quantitative measurement of clinically-relevant values of HRP2, a biomarker indicative of 
malaria infection and disease progression. This device measures directly within fingerprick 
volumes of patient serum samples, enabling new methodologies for truly point-of-care 
quantitative diagnostics. 
By providing a rapid, quantitative measurement to be deployed directly at the point-of-
care, we provide not just diagnostics but a new method for better monitoring disease 
progression and severity. These sensors can work with inexpensive electronics without the 
need for any centralized infrastructure or operator interpretation, allowing for patient- and 
community-centered surveillance and intervention. The speed of sensor response allows for 
the full measurement to take place during a single patient-doctor interaction, ensuring that no 
patient is lost to follow-up care.  
 
C. Materials and Methods 
Materials. 
Recombinant Plasmodium falciparum Histidine-Rich Protein 2 (expressed in E. coli) 
was purchased from Fitzgerald Industries International (Acton, MA) and used as received 
without further purification. 20X phosphate-buffered saline (PBS) was purchased from 
Sigma Aldrich (St. Louis, MO), diluted to 1X concentration and pH corrected to 7.4 using 
sodium hydroxide and hydrochloric acid. Bovine serum was purchased from HemoStat 
Laboratories (Dixon, CA). Oligonucleotides were synthesized by Biosearch Technologies 
(Novato, CA) and purified by dual HPLC. Bovine serum albumin, 6-mercapto-1-hexanol 
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and tris(2-carboxyethyl)phosphine were purchased from Sigma Aldrich (St. Louis, MO) and 
used as received. 
 
Microfluidic chip fabrication 
The device is comprised of an electrode substrate and channel layer. The electrode 
substrate possesses gold electrodes which are photolithographically patterned via e-beam 
evaporation onto borofloat glass substrates (thickness = 500 µm) using a chrome promotor 
layer (Cr/Au thickness = 20/200 nm). The channel layer is comprised of a double-sided 
silicon-based adhesive layer (Adhesives Research) attached to a 200 µm-thick mylar 
substrate via one of its adhesive surfaces. A laser cutter (Trotec Speedy) is used to cut the 
channel pattern in the adhesive layer (channel cross section = 140 µm x 900 µm) and the 
fluidic vias in the mylar substrate. The device is assembled by positioning and bonding the 
second adhesive surface of the channel layer onto the electrode substrate. The electrodes 
may be functionalized with the aptamer before or after assembly. 
 The microfluidic chamber was coupled to a syringe pump using pipet tips manually 
glued onto the top layer. Experiments were performed under constant flow of 10 µL/min. 
 
HRP-2 aptamer sequence. 
The aptamer sequence used is a truncated version of a previously published aptamer 
[17]. 
5’ – 6-carbon thiol linker – AGGGG TTTGG CTTTG GGTCT GGCA –  
methylene blue redox tag – 3’ 
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Sensor preparation. 
Electrodes were cleaned using repeated CV measurements in 80 mM H2SO4. DNA 
sequences were treated with a 1000-fold molar excess of tris(2-carboxyethyl)phosphine to 
reduce the 5’ disulfide modification to a free thiol. Following electrochemical cleaning, 
electrodes were immersed in 200 nM reduced DNA in 1X PBS at room temperature for 1 h 
and then moved to 20 mM 6-mercapto-1-hexanol solution in 1X PBS at 4 °C overnight. 
 
Electrochemical measurements. 
Electrochemical measurements were performed at room temperature using a PalmSens 
EmStat 3 multichannel potentiostat (PalmSens BV, Houten, The Netherlands). Square wave 
voltammetry was performed at 10 Hz using a potential step of 0.004 V and at 40 Hz, 60 Hz 
and 100 Hz using a potential step of 0.001 V, all using an amplitude of 0.025 V.  
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IV. Single-step, Calibration-Free Measurement of a Specific Protein 
Directly in Whole Blood3 
Abstract:  
Methods for the detection of diagnostically-relevant proteins are limited to either multi-
step, laboratory-based procedures, such as ELISAs, or point-of-care tests, such as lateral-
flow “dipsticks,” that merely confirm absence or presence of the protein without quantifying 
its level. Here, however, we demonstrate here the application of electrochemical aptamer-
based (E-AB) sensors to the rapid, single-step, calibration-free measurement of human 
platelet-derived growth factor (PDGF) directly in undiluted whole blood samples. 
A. Introduction 
The point-of-care measurement of diagnostically relevant molecules has the potential to 
improve clinical outcomes and reduce healthcare costs. In the developing world, for 
example, point-of-care testing is a critical substitute for laboratory testing as these resource-
limited regions often lack the infrastructure necessary to maintain and utilize a network of 
centralized clinical laboratories[1,2]. Even in the relatively advantaged developed world, 
point-of-care tests augment centralized laboratory testing by speeding diagnosis, accelerating 
the initiation of treatment and reducing the need for follow-up visits, which in turn improve 
outcomes and lower costs[3–5]. To this end, recent decades have seen the development of a 
number of point-of-care molecular diagnostics, including, for example, lateral flow “dip 
                                                 
3 This chapter in preparation for publication (with Chapter VI) as J. Somerson, N. 
Arroyo-Currás, G. Ortega, K. Ploense, H. Li, T. Kippin and K.W. Plaxco, “Nanomolar in 
vivo and calibration-free in vitro measurement of a circulating protein”. 
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sticks,” which have revolutionized the detection of pregnancy, infectious diseases, and drug 
abuse both at the point of care and in home use[6]. Dipstick tests, however, are qualitative, 
generally rendering them suitable only for the detection of health states that are binary (e.g., 
pregnant or not, using a drug or not), leaving an unmet need for point-of-care molecular 
detection platforms that are, in contrast, quantitative. Rather than reporting the mere absence 
or presence of a target, such measurements can be used to monitor the specific level of a 
given marker, providing valuable information on disease state and progression[7–9]. 
 
To achieve practicality at the point of care, a technology must be simple (single-step, 
wash-free and reagent-free), rapid (providing an answer within the 15 min of a typical 
provider/patient interaction), and low overhead (inexpensive, small)[10]. Our approach to 
achieving these ends is based on electrochemical, aptamer-based (E-AB) sensors, a 
reagentless, single-step sensing platform that couples the specificity of biomolecular 
recognition with the convenience and selectivity of electrochemical measurements (Fig. 
4.1A). E-AB sensors are comprised of a DNA aptamer artificially selected to bind the 
specific target of interest that is modified with an electrochemical reporter and attached (via 
thiol-on-gold monolayer formation) to an interrogating electrode. Upon binding its specific 
molecular target the aptamer changes conformation, which, in turn, changes accessibility of 
the electrochemical reporter to the electrode surface and generates a measurable change in 
faradaic current quantitatively related to the concentration of target present. By thus coupling 
the selectivity of biomolecular recognition with the specificity of binding-induced 
conformational changes and the quantitative value of electrochemical measurements, E-AB 
sensors are able to measure their target directly even in complex clinical media, such as 
undiluted blood serum[11–14] without the need for reagent additions, washing or any other 
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processing steps. Critically, the equipment required for this measurement is easily 
miniaturized and brought directly to the point of care, even in resource-limited settings. 
Multiple groups, for example, have described construction of laptop- or smartphone-
powered potentiostats supporting such sensors at a cost of <$100[15–18]. 
Despite the many attributes that speak to the potential utility of E-AB sensors as a point-
of-care molecular diagnostic, the platform still suffers from two significant limitations that 
have hindered the deployment of many (if not all) prior efforts to achieve practical point-of-
care molecular measurements. First, while E-AB sensors are selective enough to work in 
undiluted blood serum[11,12,19], they tend to drift when deployed in undiluted whole 
blood[20–22], thus they have historically required the conversion of blood into serum prior 
to analysis. And although such conversion is relatively straightforward[23], it requires a 
degree of infrastructure ill-suited for use at the bedside or in the developing world[24]. 
Second, the raw, absolute output signal produced by E-AB sensors varies significantly from 
sensor-to-sensor due to variation in their fabrication, a problem that continues to bedevil 
quantitative biosensor approaches[25–28]. Historically, we have solved this problem by 
calibrating each individual sensor against a standard of known (or known to be zero) target 
concentration[29,30]. Here, however, we demonstrate the ability of the E-AB platform to 
achieve reproducible, single-step measurements[31] of a specific protein target in vitro in 
unprocessed whole blood without the need for calibrating each individual sensor. 
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Figure 4.1. (A) The binding of the BB isoform of human platelet-derived growth factor 
(PDGF) to the aptamer in our sensor changes its conformation, which, in turn, renders the 
methylene blue redox reporter more accessible to the electrode surface. This change in 
accessibility results in a corresponding change in electron transfer rate, which is “read out” 
as a change in peak current when the sensor is interrogated using square wave voltammetry. 
(B) At high square-wave frequencies target binding increases the peak current (the “signal-
on” regime)[32]. (C) At low square wave frequencies (here, 10 Hz), in contrast, target 
binding is associated with a reduction in peak current. (D) Given this, there exists an 
intermediate frequency (here, 40 Hz) at which the peak current is insensitive to the presence 
or absence of target[31].  
 
B. Results 
As our protein-detecting sensor we have been exploring an E-AB sensor supporting the 
detection of the BB isoform of human platelet derived growth factor (PDGF)[12]. This 
sensor consists of a DNA aptamer binding to PDGF and modified with a thiol linker group 
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on its 5’ end and a redox active methylene blue reporter on its 3’ end (Fig. 4.1A). As noted 
above, the binding of the aptamer to its target alters the rate of electron transfer from the 
attached methylene blue, producing an easily measured change in signal when the sensor is 
interrogated via square-wave voltammetry (Fig. 4.1 B-D). The magnitude –and even the 
sign– of the resultant signal gain is a strong function of square wave frequency[32] At higher 
square wave frequencies (here > 40 Hz), which are more sensitive to rapid electron transfer, 
the peak current increases upon target binding (“signal-on”, Fig 4.1B). At lower square wave 
frequencies (< 40 Hz), the slow electron transfer of the unbound state dominates and the 
peak current decreases upon binding (“signal-off”, Fig 4.1C). Given these behaviors, there 
necessarily also exists an intermediate frequency (here, 40 Hz) at which the peak current is 
insensitive to the presence or absence of target (Fig 4.1D), which, as described below, forms 
the basis of our calibration-free measurement approach.. 
 
As is typical of such sensors, the raw current output by our PDGF-detecting E-AB 
sensor, i, varies significantly from sensor to sensor (Fig. 4.2), likely due to differences in the 
total surface area of the electrode and thus the total number and packing density of redox 
reporters that are exchanging electrons with the electrode. We have historically 
circumvented this problem via calibration using a target-free “blank.” That is, using the 
current measured in a blank, i0, we calculate “relative signal gain,” (i – i0)/i0, which, in 
contrast to absolute E-AB current, is highly reproducible from sensor to sensor[14]. Such 
calibration has proven sufficient for many applications, for example continuous monitoring 
of an exogenous target[11] or benchtop applications with blank samples readily 
available[33]. When coupled with drift correction algorithms, this calibrated approach even 
supports direct measurements in vivo in the veins of live animals[20,21]. But the need for 
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calibration increases the complexity of a point-of-care diagnostic, motivating us to pursue 
“calibration-free” measurements that can accurately quantify the concentration of a given 
molecular analyte irrespective of sensor-to-sensor fabrication variation or blood-induced 
drift[31,34].  
 
Figure 4.2. Due to variations in electrode surface area and aptamer packing density (and 
thus the total number of redox-reporters) the raw currents obtained from E-AB sensors vary 
significantly from sensor to sensor; shown in blue are the signal-on responses of three 
independently hand-fabricated, PDGF-detecting E-AB sensors. Historically we have 
corrected this variation by performing a calibration measurement in a target-free reference 
sample to determine i0, the current seen in the absence of target. Using this in conjunction 
with the signal gain,  and dissociation constant, KD, both of which are constant for all 
sensors in a given class[31], we can accurately determine target concentrations[14]. To avoid 
the need for this calibration, however, here we use measurement of the current observed at a 
square-wave frequency at which the sensor does not respond to target (iNR, red) in place of 
the calibration-derived measurement of i0. Specifically, i0 is related to iNR via a 
proportionality constant, , that is constant for all sensors employing this aptamer. Given 
this relationship, we can determine i0 from measurements of iNR performed in the sample of 
unknown concentration itself rather than in a known calibration standard. 
 
To enable calibration-free measurement we exploit the above-mentioned square-wave-
frequency dependence of E-AB signaling to generate a signal that can be used to correct for 
sensor-to-sensor variation without the need for separate calibration in a sample of known 
target concentration for each individual sensor. Specifically, because the sensor is signal-on 
at higher square wave frequencies and signal-off at lower frequencies there exists an 
intermediate frequency at which the sensor does not respond to the presence or absence of 
target (Fig. 4.1D). Provided that there is some constant ratio, , between the current 
observed at this non-responsive frequency, iNR, and the current that would be seen at the 
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signal-on frequency in a target free sample, i0, measurement of iNR in the actual sample can 
be used in place of a separate measurement in a calibration standard. As is required for this 
approach to work, the ratio of current measured at the non-responsive frequency (40 Hz for 
this sensor) to the “blank” current at the signal-on frequency (here we employ 300 Hz) is 
constant from sensor to sensor (Fig. 4.2). Using this ratio, the sensor’s known (and also 
constant) signal gain, γ, and the known (and, again, also constant) dissociation constant, KD, 
of the aptamer we can then estimate target concentration from measurements of i, and iNR 
taken in the sample itself (rather than a calibration blank) from: 
      (1) 
To determine the appropriate values of α, γ and KD for this class of E-AB sensors we 
globally fit data derived from a training set of 6 individual sensors titrated with PDGF 
directly in whole blood (Fig. S4.1), thus setting the stage for calibration free measurements 
of this protein target. A global fit of this training set produces a KD of 10.9 ± 6 nM, an   of 
3.0 ± 0.1, and a γ of 1.1 ± 0.2 for this PDGF-detecting sensor (Fig. S4.2). 
 
To test our approach, we prepared a new set of electrodes (not included in the training 
set used to define   and KD) and used them to monitor titrations of known quantities of 
PDGF in unprocessed whole blood. Using this approach, the estimated PDGF concentrations 
we derive are in good agreement with the concentration of protein added to a sample even 
when the sample is undiluted whole blood (Fig. 4.3). That is, there is an order of magnitude 
concentration range over which almost all measured points are within 50% of their known 
concentrations and more than half of the calculated values are within 20% of the known 
concentration. As a basis for comparison: the FDA recommends that home glucose meters, a 
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fully mature, commercialized technology, may have measurements within 15% of actual 
glucose values[35]. Thus, while there is room for improvement as this technology matures, 
we find this initial level of accuracy encouraging. Likewise speaking to its point-of-care 
relevance, this “calibration-free” technique does not require blank measurements, reagent 
additions or other wash steps, and thus the speed of these measurements relies only on the 
equilibration time of the sensor (<10 minutes, Fig. S4.3) and the time to take two subsequent 
electrochemical measurements in the same sample (seconds). 
 
Figure 4.3. Using our calibration-free approach we find good agreement between calculated 
protein concentrations (circles) and the known amount of protein added to each unprocessed 
blood sample (dark line). Dashed lines represent 50% (black) and 20% (gray) variance. Each 
measured concentration is calculated without calibration to any other point, and each color 
point represents a different, independently hand-fabricated sensor. 
 
Here we demonstrate the calibration-free, rapid, single-step measurement of a specific 
protein directly in whole, unprocessed blood using a convenient, single-step platform 
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seemingly well suited for point-of-care applications. This approach expands the utility of this 
point-of-care clinical technology to enable quantitative, single-step measurement of protein 
biomarkers of disease, endogenous levels of protein biomarkers and metabolites, and protein 
markers of disease progression. As this technique is limited only by the development of 
suitable aptamers, this method should be broadly applicable to any protein target of interest, 
especially as aptamer selection techniques continue to improve.  
 
 
Figure S4.1. Global fitting of the outputs of PDGF-detecting sensors in undiluted whole 
blood. We globally fit the output of a training set of six sensors to Eq. 4 to define KD, , 
and  for this type of sensor under the conditions employed (whole blood, room 
temperature). The solid lines illustrate how well the globally fit parameters describe the 
output of each individual sensor. Each color line corresponds to the fit for the electrode with 
the same color points, though the fits overlap. 
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Figure S4.2. Optimized parameters obtained via global fitting. The squared errors in the 
fittings (Fig. S4.1) were propagated by Monte-Carlo analysis (10,000 steps) in order to 
provide a distribution of the variability in the calculated parameters KD,  and . 
 
 
Figure S4.3. Rapid response of sensors to target. Following addition of target into flowing 
buffer, sensor signal is within error of the equilibrium value within 10 minutes. Shown are 
the mean of six electrodes with error bars representing the standard deviation. 
C. Materials and Methods 
Materials. 
Human recombinant Platelet-derived Growth Factor-BB (expressed in E. coli) was 
purchased from Prospec-Tany Technogene Ltd. (Ness Ziona, Israel) and used as received 
without further purification. PDGF-BB was dissolved in water to a concentration of 10.3 µM 
(250 µg/mL) then further diluted for titration in the same media as measurements were 
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performed. 20X phosphate-buffered saline (PBS) was purchased from Sigma Aldrich (St. 
Louis, MO), diluted to 1X concentration and pH corrected to 7.4 using sodium hydroxide 
and hydrochloric acid. Whole bovine blood and bovine plasma were purchased from 
HemoStat Laboratories (Dixon, CA). Blood was shipped with 3 IU/mL sodium heparin and 
used within a week of receipt. Gold wire was purchased from A-M Systems (Sequim, WA). 
Heat-shrink PTFE was purchased from Zeus Labs (Branchburg Township, CA). 
Oligonucleotides were synthesized by Biosearch Technologies (Novato, CA) and purified by 
dual HPLC. 6-mercapto-1-hexanol and tris(2-carboxyethyl)phosphine were purchased from 
Sigma Aldrich (St. Louis, MO) and used as received. 
PDGF-BB aptamer sequence. 
5’ – 6-carbon thiol linker – CAGGC TACGG CACGT AGAGC ATCAC CATGA 
TCCTG – methylene blue redox tag – 3’ 
Sensor preparation. 
Our biosensor consists of a 200 µm diameter gold wire covered with heat-shrinkable 
PTFE insulation. A window of bare gold was then coated with a mixed self-assembled 
monolayer of thiol-modified DNA strands and 6-mercapto-1-hexanol. Electrodes were 
electrochemically roughened and cleaned as previously described[21]. DNA sequences were 
treated with a 1000-fold molar excess of tris(2-carboxyethyl)phosphine to reduce the 5’ 
disulfide modification to a free thiol. Following electrochemical cleaning, electrodes were 
immersed in 200 nM reduced DNA in 1X PBS at room temperature for 1 h and then moved 
to 20 mM 6-mercapto-1-hexanol solution in 1X PBS at 4 °C overnight. 
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Electrochemical measurements. 
Electrochemical measurements were performed at room temperature using a CHI630C 
potentiostat with a CHI684 multiplexer (CH Instruments, Austin, TX) and a standard-three 
electrode cell containing a platinum wire counter electrode and an Ag/AgCl reference 
electrode (both from CH Instruments, Austin, TX). Square wave voltammetry was 
performed at 300 Hz using a potential step of 0.001 V, 10 Hz using a potential step of 0.004 
V and at 40 Hz using a potential step of 0.001 V, all using an amplitude of 0.025 V. All 
experiments were conducted in a closed-loop system with a continuous flow of test media 
(~1 mL/s) using a circulator pump (Cole-Parmer, Vernon Hills, IL).  
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V. Real-Time Measurement of Small Molecules Directly in Awake, 
Ambulatory Animals4 
Abstract:  
The development of a technology capable of tracking the levels of drugs, metabolites, 
and biomarkers in the body continuously and in real-time would advance our understanding 
of health and our ability to detect and treat disease. It would, for example, enable therapies 
guided by high-resolution, patient-specific pharmacokinetics (including feedback-controlled 
drug delivery), opening new dimensions in personalized medicine. In response, we 
demonstrate here the ability of electrochemical aptamer-based (E-AB) sensors to support 
continuous, real-time, multi-hour measurements when emplaced directly in the circulatory 
systems of living animals. Specifically, we have used E-AB sensors to perform the multi-
hour, real-time measurement of four drugs in the bloodstream of even awake, ambulatory 
rats, achieving precise molecular measurements at clinically relevant detection limits and 
high (3 s) temporal resolution, attributes suggesting the approach could provide an important 
new window into the study of physiology and pharmacokinetics. 
Significance 
The ability to monitor arbitrary molecules directly in living subjects as they undergo their 
daily routines remains one of the “holy grails” of bioanalytical chemistry. Such a technology 
would, for example, vastly improve our knowledge of physiology, pharmacokinetics, and 
                                                 
4 This chapter adapted from Arroyo-Currás, N.; Somerson, J.; Vieira, P. A.; Ploense, K. 
L.; Kippin, T. E.; Plaxco, K. W. Real-time measurement of small molecules directly in 
awake, ambulatory animals. Proc. Natl. Acad. Sci. 2017, 114, 645–650, 
doi:10.1073/pnas.1613458114, reprinted with permission. 
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toxicology by allowing the high-precision measurement of drugs, metabolites and 
biomarkers under realistic physiological conditions. Such a technology would also provide 
an unparalleled, real-time window into health status (e.g., monitoring kidney or endocrine 
function by measuring creatinine or hormones) and would facilitate “therapeutic drug 
monitoring,” in which dosing is personalized to the accurately measured metabolism of each 
individual patient. Finally, the ability to measure molecules in the body continuously and in 
real time would provide unprecedented new routes by which drugs with dangerously narrow 
therapeutic windows or complex optimal dosing regimens could be safely and efficiently 
administered. 
 
A. Introduction 
The availability of versatile and convenient sensors supporting the continuous, real-time 
measurement of specific molecules directly in the body could prove transformative in 
research and in medicine. In the short term, for example, such an advance would allow the in 
vivo concentrations of drugs, metabolites, hormones, and other biomarkers to be measured 
with high precision in subjects as they undergo their normal daily routine, improving our 
knowledge of physiology, pharmacokinetics, and toxicology. On longer timescales, such an 
advance would facilitate “therapeutic drug monitoring,” in which dosing is personalized 
using a patient’s directly measured (rather than crudely and indirectly estimated) 
metabolism. By permitting the continuous monitoring of biomarkers (e.g., creatinine and 
hormones), such a technology would likewise provide a new and highly detailed window 
into health status (e.g., kidney or endocrine function). Finally, the real-time measurement of 
specific molecules in the body would advance drug delivery (1). Such a technology, for 
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example, could easily support feedback-controlled dosing, in which the delivery of drugs is 
adjusted in real time based on their concentration in the body or on the body’s molecular-
level response to treatment. This real-time, feedback-controlled drug delivery would provide 
new routes by which drugs with dangerously narrow therapeutic windows or complex 
optimal dosing regimens can be administered safely and efficiently.  
Although technologies already exist for the continuous or near-continuous measurement 
of a small number of metabolites [e.g., glucose (2) and lactate (3)] and neurotransmitters 
[e.g., dopamine (4, 5), serotonin (6), glutamate (7), and acetylcholine (8)] in vivo, these 
approaches all rely on the specific chemical reactivities of their targets (e.g., the redox 
chemistry of the analyte or its ability to be oxidized by a specific enzyme). Because of their 
dependence on reactivity, these technologies are not generalizable to the detection of many 
other physiologically or clinically important molecules, and there remains an open, critical 
need for strategies that support the continuous detection of specific molecules in the body 
irrespective of their reactivity. Unfortunately, however, serious technical hurdles stand in the 
way of realizing this goal (9, 10). First, to support continuous measurements, a sensor cannot 
rely on batch processing, such as wash or separation steps. Second, to support in vivo 
measurements, a sensor cannot use exogenously added reagents and must remain stable 
against prolonged exposure to blood or interstitial fluids in vivo. To date, the vast majority 
of molecular detection strategies have failed to meet one or both of these critical challenges. 
Chromatography, mass spectrometry, and immunochemistry, for example, are complex, 
multistep batch processes requiring wash steps, separation steps, and/or sequential reagent 
additions, hindering their ability to perform continuous measurements. Conversely, whereas 
biosensors based on surface plasmon resonance (SPR), quartz crystal microbalances (QCM), 
field-effect transistors (FET), and microcantilevers all support continuous, real-time 
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operation, each fails when challenged in blood (much less in vivo) due to their inability to 
discriminate between the specific binding of their target and the nonspecific adsorption of 
proteins and cells (11–14). Here, in contrast, we demonstrate the ability of electrochemical 
aptamer-based (E-AB) sensors, a sensing platform adaptable to the detection of any of a 
wide range of molecular targets irrespective of their chemical reactivity, to support 
continuous, real-time measurements directly within the body.  
The generality of E-AB sensors stems from the versatile recognition and signal-
transduction properties of aptamers, nucleic acids selected for their ability to bind specific 
molecular targets (15). Created using well-established in vitro selection methods (16, 17), 
aptamers can be generated that bind a wide range of analytes (18) and can be rationally 
reengineered such that they undergo a large-scale conformational change upon binding these 
analytes (19) over arbitrarily broad (20, 21) or narrow (20, 22) concentration windows. E-
AB sensors use this conformational change to generate an easily measurable electrochemical 
signal without the need for the target to undergo a chemical transformation (23). To achieve 
this signal transduction, the aptamer’s binding-induced conformational change is used to 
alter the efficiency with which a covalently attached redox reporter (here methylene blue) 
approaches an underlying electrode, producing a target-concentration-dependent change in 
current when the sensor is interrogated using square wave voltammetry (24) (Fig. 5.1A and 
Fig. S5.1). As required to support continuous in vivo measurements, E-AB signaling is not 
reliant on batch processes, such as wash steps, or on the addition of exogenous reagents. 
Furthermore, because E-AB signaling is generated by a specific, binding-induced 
conformational change—and not adsorption of the target to the sensor surface (which is the 
case for SPR, QCM, FETs, and microcantilevers)—the platform is relatively insensitive to 
fouling. Previous studies, for example, have shown that E-AB sensors perform well when 
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challenged for hours in flowing, undiluted blood serum (25), rendering them one of the most 
fouling resistant single-step biosensor platforms reported to date.  
Despite their unprecedented ability to perform continuous monitoring in undiluted blood 
serum, first-generation E-AB sensors nevertheless foul when challenged in undiluted whole 
blood, precluding their use directly in vivo. In response, we previously developed a 
microfluidic approach to preventing fouling by blood cells that supports continuous ex vivo 
measurements of drug levels in blood continuously drawn by catheter from anesthetized 
animals (26). In that work, we constructed a microfluidic device using two stacked laminar 
flows: a bottom flow of blood continuously drawn via a jugular catheter from the animal and 
draining into a waste chamber, and a flow of buffer stacked on top of this first layer and in 
permanent contact with the relevant E-AB sensor. The buffer sheath acts as a continuous-
flow diffusion filter, allowing for rapid diffusion of small-molecule targets to the sensor 
while preventing the approach of (much more slowly diffusing) blood cells. Using this 
device, we have measured the serum levels of multiple drugs for up to 4 h. The approach, 
however, is nevertheless not without potentially significant limitations. Being ex vivo, for 
example, the device suffers from a time lag (the time required for blood to leave the body 
and enter the device), requires continuous blood draws (the buffer-diluted blood must be 
discarded), and can only be used to measure molecules in blood because other bodily fluids 
cannot easily and continuously be withdrawn. The device is also complex, requiring a pump 
and buffer and waste reserves. Finally, due to the necessity of generating laminar flow, the 
device is sensitive to mechanical shock and thus likely not robust enough to be deployed in 
awake, freely moving animals. Here, in contrast, we have adapted E-AB sensors to the 
important problem of performing continuous, real-time, multihour measurements of specific 
molecules directly within the bodies of awake, freely moving animals. 
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B. Results and Discussion 
 
Figure 5.1. Real-time, continuous measurement of specific drugs directly in the living body. 
(A) The E-AB sensing platform, in which the binding-induced folding of an electrode-
bound, redox-reporter-modified aptamer leads to a change in electron transfer easily detected 
using square wave voltammetry. (B) A microporous (0.2 μm) polysulfone membrane 
protects the sensor from fouling by blood cells. (C) The resultant device is small enough to 
emplace in one of the external jugulars of a rat using an 18-gauge catheter (the cartoon 
overlay illustrates sensor location). (D) To correct the drift seen in vivo, we record data at 
two square wave frequencies (here 30 and 240 Hz; optimal values depend on the aptamer 
used). At one frequency, the sensor’s voltammetric signal increases upon target binding, 
whereas at the other, it is reduced; taking the difference between the two eliminates drift and 
enhances signal-to-noise (26). (E) Using drift-corrected E-AB sensors, we have monitored 
the in vivo concentrations of multiple drugs continuously and in real-time over the course of 
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many hours in measurements that achieve clinically relevant precision and few-second time 
resolution. Shown here, for example, is the measurement of the antibiotic tobramycin in the 
blood of an anesthetized rat after two serial injections into the opposite external jugular. (F) 
At 3 s per measurement, the time resolution of these measurements is sufficient to monitor 
both the injection itself and the subsequent distribution of the drug within the circulatory 
system and reflects an orders of magnitude improvement over the resolution of traditional 
pharmacokinetic methods (45). 
 
We have taken a two-pronged approach to circumventing the challenging conditions 
associated with deploying sensors directly within the bodies of living animals. To reduce 
fouling, we encase our sensors in biocompatible (27) polysulfone membranes (Fig. 5.1B), 
the 0.2-μm pores of which prevent blood cells from approaching the sensor surface while 
simultaneously allowing for the rapid transport of target molecules. Using these membranes, 
we achieve stable E-AB baselines in flowing, undiluted whole blood in vitro over many 
hours (Fig S5.1). Even membrane-protected E-AB sensors, however, exhibit significant 
baseline drift when emplaced in the veins of live animals (Fig. 5.1D). To circumvent this 
drift, we use a correction scheme termed “Kinetic Differential Measurements” (KDM). Drift 
correction methods have historically used a physically separate reference that, although 
unresponsive to the targeted input, nevertheless yields an identical response to background 
that can be subtracted from the sensor output (28). KDM instead employs a single aptamer in 
both roles, thus obviating the need to fabricate a matched sensor-reference pair (26). To 
achieve this stand-alone performance, KDM exploits the square wave frequency dependence 
of E-AB signaling. Specifically, electron transfer is more rapid from the folded, target-bound 
aptamer than it is from the unfolded, target-free aptamer. This kinetic difference results in a 
binding-induced increase in current when we perform square-wave voltammetry at high 
frequencies and a binding-induced decrease in signal at low frequencies (Fig. S5.2) (19). 
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Conveniently, these two outputs drift in concert, and thus taking their difference effectively 
corrects baseline drift (Fig. 5.1D).  
Drift-corrected, membrane-protected E-AB sensors readily support the continuous, 
seconds-resolved real-time measurement of specific molecules in the blood of living animals 
(Fig. 5.1 E and F). To demonstrate this ability, we first emplaced E-AB sensors for the 
detection of the cancer chemotherapeutic doxorubicin (DOX) (29, 30) in the external jugular 
vein of anesthetized Sprague–Dawley rats (Fig. 5.1C). Using this approach, we achieve 
nanomolar precision in the measurement of clinically relevant plasma drug levels following 
five sequential injections over 5 h of continuous monitoring (Fig. 5.2A). The resulting plot 
of concentration versus time presents consecutive spikes corresponding to each of the 
injections performed, with maximum DOX concentrations (C max ) of ∼600 nM and the 
effective clearance of 90% of the drug from the circulatory system within 50 min, values in 
close accord with prior reports (31).  
Because E-AB signaling is independent of the chemical reactivity of the target, E-AB 
sensors can be switched to the detection of new, chemically unrelated molecules via the 
simple expedient of replacing their aptamer recognition element. To demonstrate this 
modularity, we fabricated sensors using an aptamer recognizing the aminoglycoside 
antibiotics (32, 33). Using these sensors, we first followed monotonically increasing i.v. 
doses of kanamycin spanning the therapeutic ranges used in humans (34) (10–30 mg/kg) and 
animals (35) (25–30 mg/kg). The sensor responded rapidly to each injection, measuring 
maximum concentrations between 34 and 400 μM depending on the delivered dose (Fig. 
5.2B). The 200 μM maximum concentration observed after a 10 mg/kg dose was in 
agreement with peak plasma concentrations determined previously (using cumbersome, 
poorly time-resolved ex vivo radioimmunoassays) after similar doses were injected into 
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multiple animal species (36). The sensor can likewise monitor in real time the in vivo 
concentrations of the aminoglycosides gentamycin (Fig. 5.2C) and tobramycin (Fig. 5.2D 
and Fig. S5.3) following either i.m. or i.v. injections, applications in which it once again 
achieves excellent precision and time resolution.  
 
Figure 5.2. Continuous molecular measurements in vivo. We have successfully measured 
multiple drugs using E-AB sensors emplaced in the jugulars of anesthetized rats. (A) Shown 
here are five i.v. injections of 2 mg/m 2 of the cancer chemotherapeutic DOX, a dose more 
than 25 times lower than typical human doses (46). (B–D) To illustrate the generality of the 
approach, we have also used an aminoglycoside-detecting E-AB sensor to monitor in vivo 
levels of the antibiotics kanamycin, gentamicin, and tobramycin at the indicated doses. The 
kanamycin doses used here span the 10–30 mg/kg therapeutic range used in humans (34). 
For gentamicin, we focus here on two sequential i.v. injections of the drug, separated by a 2-
h interval. For tobramycin, we present an overlay of data collected after sequential i.m. 
(thigh) and i.v. (the external jugular opposite the sensor) injections carried out in a single rat. 
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The ability to perform the continuous measurement of specific molecules in the body 
opens the door to many potentially transformative applications in the study of physiology 
and pharmacokinetics. For example, the few-second time resolution of E-AB sensors (Fig. 
5.1F), which reflects orders of magnitude improvement over the time resolution of 
traditional pharmacokinetic methods, is sufficient to measure the kinetics with which drugs 
distribute following i.v. injection (Fig. 5.3 and Fig. S5.4), a pharmacokinetic phase that has 
rarely if ever been previously measured (e.g., refs. 37–39). Indeed, the precision of E-AB 
measurements is sufficient not only to robustly identify animal-to-animal pharmacokinetic 
variability, but even variability within a single animal over the course of a few hours. To 
explore this ability, we monitored the pharmacokinetics of tobramycin following sequential 
20 mg/kg i.v. injections conducted 2 h apart in each of three rats. Fitting the resultant data to 
a two-compartment model, we easily observe statistically significant inter- and even 
intraanimal variability (Fig. 5.4). The distribution phase (α phase) of this drug, for example, 
is defined largely by blood and body volume and thus, although the distribution differs 
between animals, it differs much less as a function of time within individual animals. The 
elimination kinetics of tobramycin (β phase), in contrast, not only vary significantly between 
animals but also exhibit variations within a single individual over the course of a few hours 
that are easily measurable using our approach (Table 5.1). For example, although the 
kinetics of the α phase remain relatively constant for a given animal, the β phase invariably 
slows with time. This change presumably occurs because, whereas drug absorption (captured 
by the α phase) is defined by body volume, which remains fixed, the elimination of 
tobramycin (captured in the β phase) is predominantly via excretion from the kidneys (40, 
41), the function of which likely changes due to alterations in the animal’s blood pressure 
(42) and/or hydration after several hours under anesthesia.  
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Figure 5.3. 3. High-precision pharmacokinetics. Shown are high-resolution pharmacokinetic 
profiles for the drugs DOX (A) and gentamicin (B) upon i.v. injection of 50 mg/m 2 and 20 
mg/kg doses, respectively. As is easily seen, the resolution of in vivo E-AB sensors is 
sufficient not only to define the slower β phases of these drugs (red dots) but also to define 
their much more rapid α phases (blue dots) with excellent statistical significance. These 
measurements constitute a precise determination of the i.v. distribution phase of a small-
molecule drug. 
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Figure 5.4. The measurement of inter- and intraanimal pharmacokinetic variability. The 
precision of E-AB measurements is sufficient to measure not only interanimal 
pharmacokinetic variability but also variability within an individual animal over time. 
Shown are the pharmacokinetic profiles of the drug tobramycin following two sequential 20 
mg/kg i.v. injections in three different rats (A, B, and C). These high-precision 
measurements reveal a decrease in the rate of drug elimination kinetics (β phase) in the 
second injection with respect to the first in all three animals, an effect that presumably arises 
due to changes in the animal’s blood pressure and/or hydration after several hours under 
anesthesia. The bold black lines represent the mathematical fit of each injection dataset to a 
two-compartment pharmacokinetic model. 
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Rat 
no. 
Injection 
no. 
A,* µM α, min B, µM β, min Cmax, †µM 
AUC, 
µmol·min·L-1 
ClT, 
mL·min-1 
1 1 255 ± 82 2.2 ± 0.4 71 ± 2 51 ± 3 328 ± 82 117 ± 58 129 ± 64 
1 2 267 ± 56 1.6 ± 0.3 80 ± 4 57 ± 4 347 ± 56 168 ± 61 90 ± 32 
2 1 113 ± 38 1.6 ± 0.4 82 ± 2 32 ± 1 195 ± 38 73 ± 39 201 ± 100 
2 2 109 ± 22 2.7 ± 0.6 50 ± 2 71 ± 7 159 ± 22 41 ± 15 370 ± 139 
3 1 284 ± 34 1.2 ± 0.1 46 ± 2 38 ± 3 330 ± 34 237 ± 49 63 ± 13 
3 2 138 ± 32 1.7 ± 0.1 35 ± 2 67 ± 3 173 ± 32 82 ± 28 186 ± 63 
Table 5.1. Pharmacokinetic parameters corresponding to repeated i.v. injections of 
tobramycin in three Sprague-Dawley rats. 
Confidence ranges reflect 95% confidence intervals. 
*A, α, B and β are derived from the fit to a two compartment model: [target] = Ae-t/α + Be-t/β, 
where α and β are the half-lives for distribution and elimination, respectively. 
† Cmax, AUC (area under the curve), ClT (drug clearance), and their associated confidence intervals propagated 
from the kinetic parameters A, α, B and β. 
 
The ability of E-AB sensors to reject false signals arising from background interferents is 
excellent; none of the many endogenous metabolites and hormones in rat blood activates the 
sensor, as evidenced by their performance in vivo. The platform’s ability to distinguish 
between structurally similar molecules, in contrast, can be problematic due to the sometimes 
[although not always (43, 44)] limited specificity of aptamers because, of course, the sensor 
cannot be more specific than the aptamer from which it is constructed. E-AB specificity is 
nevertheless sufficient for many research and clinical applications. For example, although 
the aminoglycoside-binding aptamer recognizes multiple members of this closely related 
family of drugs (Fig. 5.2 B–D), coadministration of more than one of these highly toxic 
drugs is clinically contraindicated, and thus the inability to distinguish between them is of 
little medical relevance. The therapeutic action of DOX is driven by its ability to bind DNA, 
and thus the aminoglycoside sensor also exhibits cross-reactivity to this drug (Fig. S5.5A). 
Here too, however, the coadministration of the two is so rare as to limit the clinical impact of 
this effect. The DOX-detecting sensor, in contrast, exhibits no significant cross-reactivity 
with the aminoglycosides (Fig. S5.5B), nor does it exhibit significant cross-reactivity with 
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other chemotherapeutics that are commonly coadministered with DOX in clinical 
applications (26).  
In addition to studies, as those above, performed on anesthetized animals, the simplicity, 
physical robustness, and small size of E-AB sensors also renders it possible to perform 
measurements on awake, ambulatory animals. To illustrate this ability, we surgically 
implanted permanent catheters in the jugular veins of rats and allowed the animals to recover 
from this surgery for 2 wk before using the catheter to insert a flexible E-AB sensor under 
light anesthesia. The sensor connects to its supporting electronics via flexible wire leads that 
allow the awake animals to move largely unimpeded (Fig. 5.5A). Aminoglycoside sensors 
used under these conditions support run times of up to half a day as the animal feeds, drinks, 
and explores its environment (Fig. 5.5 B and C), producing pharmacokinetic data that avoid 
potentially confounding factors associated with measurements based on (repeated) blood 
draws, which require anesthetized or otherwise immobilized (and thus stressed) animals.  
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Figure 5.5. Continuous, in vivo molecular measurements on awake, ambulatory animals. 
(A) The small size and physical robustness of E-AB sensors renders it possible to use them 
in animals as they eat, drink, and explore their cage. This robustness, in turn, enables the 
measurement of specific molecules in the blood of animals as they undertake their normal 
daily routine, conditions perhaps more relevant to human health than those traditionally used 
for the collection of metabolic and pharmacokinetic data. Shown are blood levels of the drug 
tobramycin after a 25 mg/kg i.m. injection (thigh) (B) or sequential 40 mg/kg i.v. (jugular 
vein) injections (C) in awake, freely moving animals. 
 
Here, we demonstrate the ability of E-AB sensors to track specific small molecules 
continuously and in real time in awake, ambulatory animals, a capability that could provide 
an important tool for understanding physiology and pharmacology. By allowing arbitrary 
molecules (limited only by the availability of an aptamer of appropriate specificity and 
affinity) to be monitored with high resolution in animals undergoing their normal daily 
routine, for example, the ability to perform such measurements could improve our 
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knowledge of metabolism, pharmacokinetics, and toxicology. The few-second time 
resolution of our approach likewise suggests that it could improve our understanding of 
rapidly fluctuating physiological events, such as uptake and distribution pharmacokinetics, 
hormone and neurotransmitter release, and the movement of drugs and metabolites across 
the blood–brain barrier and within the central nervous system. Finally, the ability to perform 
the measurement of specific molecules in the body in real time could enhance the efficiency 
and accuracy with which drugs are dosed, in applications ranging from personalized, patient-
specific pharmacokinetic measurements as a means of precisely tailoring dosing to long-term 
feedback-controlled drug delivery in which the dosage of a drug is varied in real time in 
response to minute-to-minute changes in a patient’s physiological status. In short, the 
technology demonstrated here could enhance not only our understanding of health but also 
our ability to detect, monitor, and treat disease. 
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Figure S5.1. Continuous measurements in flowing whole blood in vitro. (A) This plot 
shows a comparison of baseline drift between the membrane-modified platform described in 
this work (no current change in 6 h) and conventional aminoglycoside E-AB sensors (40% 
current loss in 6 h). Normalized currents correspond to peak currents from square-wave 
voltammograms divided by the peak current of the first voltammogram. (B) Membrane-
protected, KDM-corrected sensors respond identically to two identical injections of 1 mM 
kanamycin without loss in signal after even hours in flowing whole blood, illustrating the 
extent to which KDM-corrected sensors remain accurate even under these challenging 
conditions. Note that the sensor response time is slower in these in vitro experiments than in 
our in vivo experiments, likely due to the much slower flow velocities found in this artificial 
circulatory system than in the actual circulatory system of the rat. (C) Membrane-free 
sensors, in contrast exhibit significant signal decay due to cellular fouling. Errors correspond 
to the standard deviation observed across 3 independently fabricated sensors.  
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Figure S5.2. Kinetic Differential Measurements exploit the difference in current decay 
rates between the bound and unbound state of the aptamer. (A) Shown is a cyclic 
voltammogram recorded at 100 mV s-1 (negative current for reduction) from an 
aminoglycoside-detecting E-AB sensor. This voltammogram presents the voltage limits 
where no current is passing through the working electrode (0.0 V) and where the reduction 
of methylene blue can be carried out at constant potential (for example, -0.31 V). (B) 
Stepping the potential of this same sensor from 0.0 V to -0.31 V produces 
chronoamperometric measurements that can be used to illustrate the KDM method. Here, the 
current-time curves were recorded in the absence and presence of target (1 mM tobramycin), 
with a sampling rate of one point per millisecond. Because the rates of current decay are 
different for the two states (i.e., the target-bound aptamer transfers electrons more rapidly 
than the target-free state), sampling the current 33 ms after the jump (corresponding to a 
square-wave frequency of 30 Hz) produces a decrease in signaling current upon target 
binding. In contrast, sampling 4.2 ms after the pulse (corresponding to a square wave 
frequency of 240 Hz) produces a current increase.  
 
A B 
Binding 
increases 
current 
Binding 
decreases 
current 
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Figure S5.3. Continuous measurement of the antibiotic tobramycin in the bloodstream 
of an anesthetized rat. Shown are data collected on a living rat given two sequential 20 
mg/kg intravenous injections of the drug. 
 
 
 
Figure S5.4. Pharmacokinetics of doxorubicin in vivo. Shown is an average of five 2 
mg/m2 injections of doxorubicin measured in the jugular vein of a single rat (from Fig. 
5.2A). The indicated fit is to a two-compartment pharmacokinetic model. 
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Figure S5.5. Cross-reactivity studies of E-AB sensors deployed in living rats. The 
specificity of E-AB sensors cannot be greater than that of the aptamers from which they are 
constructed, and the specificity of aptamers targeting small molecules is sometimes limited. 
Here we show the response of (A) an aminoglycoside-sensing E-AB sensor and (B) a DOX-
sensing E-AB sensor emplaced in the right jugular veins of rats to serial intravenous 
injections of 8 mg/m2 DOX and of 25 mg/kg tobramycin, respectively.  
B A 
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Figure S5.6. Titration curves for aminoglycoside- and doxorubicin-detecting E-AB 
sensors in flowing whole blood in vitro. (A) To illustrate the use of KDM with 
aminoglycoside-detecting sensors we show titration curves for kanamycin (Kd = 800 µM) 
recorded at 60 Hz and 500 Hz and the KDM-corrected curve that is the difference between 
the two. (B, C) KDM-corrected curves are shown here for gentamicin (Kd = 700 µM) and 
tobramycin (Kd = 790 µM). (D) To illustrate the use of KDM with doxorubicin-specific 
sensors (Kd = 5 µM) we present titration curves for doxorubicin recorded at 10 Hz and 120 
Hz and the KDM-corrected curve that is the difference between the two. In the case of 
doxorubicin, data was normalized versus a point recorded in the absence of target, hence the 
small offset observed in the y-axis. Errors correspond to the standard deviations observed 
across three independently fabricated and tested sensors. 
A B 
C D 
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C. Materials and Methods 
Chemicals and Materials 
Sodium hydroxide, sulfuric acid, tris(hydroxymethyl)aminomethane (Tris), 
ethylenediaminetetraacetic acid (EDTA), sodium hydrogen phosphate, sodium chloride, 
potassium chloride, and potassium dihydrogen phosphate were ordered from Fisher 
Scientific (Waltham, MA). 6-Mercapto-1-hexanol and tris(2-carboxyethyl)phosphine were 
ordered from Sigma Aldrich (St. Louis, MO). Tobramycin sulfate, gentamycin sulfate, and 
kanamycin monosulfate were ordered in USP grade from Gold BioTechnology, Inc (St. 
Louis, MO). Doxorubicin hydrochloride was ordered from LC Laboratories (Woburn, MA). 
A 1X stock solution of phosphate buffered saline (PBS) was prepared by mixing 8 g of 
sodium chloride, 0.2 g of potassium chloride, 1.44 g of sodium hydrogen phosphate, and 
0.24 g of potassium hydrogen phosphate in 800 mL of distilled water. The pH of this 
solution was adjusted to 7.4 using hydrochloric acid and the volume was adjusted to 1 L. A 
1X stock solution of Tris-EDTA buffer was prepared by mixing 1 ml of 1 M Tris-HCl (pH 
8.0) with 0.2 ml EDTA (0.5 M), adjusting the final volume to 100 mL. All chemicals were 
used as received. Heparinized human and bovine blood for flowing in vitro measurements 
were purchased from Hemostat Laboratories (Dixon, CA). 
The E-AB sensors employed here were adapted from previous work.29,32,33 To fabricate 
them we ordered the relevant methylene-blue-and-thiol-modified DNA constructs from 
Biosearch Technologies. The 5’ end of each is modified with a thiol on a 6-carbon linker and 
the 3’ end is modified with carboxy-modified methylene blue attached to the DNA via the 
formation of an amide bond to a primary amine on a 7-carbon linker (Table 1). The length of 
the surface tethering carbon linker represents a compromise between the two main criteria 
for electrochemical biosensor applications: stability and electron-transfer efficiency. We 
selected a 6-carbon linker because it exhibits good stability and improved signaling relative 
to that seen, for example, when using 11-carbon linkers.47 The modified DNAs were purified 
through dual HPLC by the supplier and used as received. Upon receipt each construct was 
dissolved to 200 μM in 1X Tris-EDTA buffer and frozen at -20 °C in individual aliquots 
until use. 
 
 
Table S5.1. DNA aptamer sequences used in this work.  
 
Aptamer Sequence 
Doxorubicin 5’ – HS- (CH2)6 – ACCATCTGTGTAAGGGGTAAGGGGTGGT – (CH2)7 –NH– Methylene Blue – 
3’  
Aminoglycoside 
5’ – HS- (CH2)6 – GGGACTTGGTTTAGGTAATGAGTCCC – (CH2)7 –NH– Methylene Blue – 3’ 
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Catheters (18G) and 1 mL syringes were purchased from Becton Dickinson (Franklin 
Lakes, NJ). Silver wire (200 µm diameter) was purchased from Alfa Aesar (Ward Hill, MA); 
to employ this as a reference electrode it was immersed in bleach overnight to form a silver 
chloride film. Gold-plated tungsten wire (100 µm diameter) was purchased from 
GoodFellow (Huntingdon, England). Insulated pure gold and silver wires (100 µm diameter) 
were purchased from A-M systems. Polyethersulfone membranes (P/N: C02-E20U-05-N) 
were purchased as MicroKros Filter Modules from Spectrum Laboratories (Rancho 
Dominguez, CA). The filter modules were cut open and the hollow membranes were 
extracted from them. Heat-shrink polytetrafluoroethylene insulation (PTFE, HS Sub-Lite-
Wall, 0.02, 0.005, 0.003±0.001 in, black-opaque, Lot # 17747112-3) to use on gold-plated 
tungsten wires was purchased from ZEUS (Branchburg Township, CA).  
 
Sensor Fabrication 
Segments of either gold-plated tungsten wire (anesthetized animals) or more malleable 
pure gold wire (awake animals) 7 cm in length were cut to make sensors. These wires were 
then insulated by applying heat to shrinkable tubing around the body of the wires, as 
depicted in Fig. 5.1B. The sensor window (i.e., the region without insulation) was 
approximately 5-8 mm in length. To increase surface area of these working electrodes (to 
obtain larger peak currents) the sensor surface was roughened electrochemically via 
immersion in 0.5 M sulfuric acid followed by jumping between Einitial = 0.0 V to Ehigh = 2.0 
V vs Ag/AgCl, back and forth, for 100,000 pulses. Each pulse was of 2 ms duration with no 
“quiet time.”  
To fabricate sensors an aliquot of the appropriate DNA construct was thawed and then 
reduced for 1 h at room temperature with a 1000-fold molar excess of tris(2-
carboxyethyl)phosphine. A freshly roughened gold electrode was then rinsed in di-ionized 
water before being immersed in a solution of the appropriate reduced DNA construct at 200-
500 nM in PBS for 1 h at room temperature. Following this the sensor was inserted into 
hollow polysulfone fibers 1.5 cm in length and 200 µm in diameter. The membranes were 
mechanically attached to the sensors by wrapping the edges with parafilm™. After attaching 
the membranes, the sensors were immersed overnight at 4°C for 12 h in 20 mM 6-mercapto-
1-hexanol in PBS to coat the remaining gold surface and remove nonspecifically adsorbed 
DNA. After this the sensors were rinsed with di-ionized water and stored in PBS.  
 
Electrochemical Methods and Data Processing 
For all sensing experiments, the sensors were interrogated using square wave 
voltammetry from 0.0 V to -0.5 V vs. Ag/AgCl, using an amplitude of 50 mV, potential step 
sizes of 1-5 mV, and varying frequencies from 10 Hz to 500 Hz. The files corresponding to 
each voltammogram were recorded in serial order using macros in CH Instruments software. 
The post-experiment analysis of results was carried out using a script coded in Igor Pro 7 (SI 
Appendix, p.13).  
All in vitro measurements were performed using a three-electrode setup and with a CH 
Instruments electrochemical workstation (Austin, TX, Model 660D) using commercial 
Ag/AgCl reference electrodes filled with saturated KCl solution and platinum counter 
electrodes.  
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All in vivo measurements were performed using a two-electrode setup in which the 
reference and counter electrodes were a silver wire coated with a silver chloride film as 
described above. The measurements carried out in vivo were recorded using a handheld 
potentiostat from CH Instruments (Model 1242 B). 
 
In vitro Experiments 
To measure aptamer affinity and correlate signal gain to target concentration, sensors 
were interrogated by square-wave voltammetry first in flowing PBS and next in flowing 
heparinized human or bovine blood with increasing concentrations of the corresponding 
target. These experiments were carried out in a closed flow system intended to mimic the 
type of blood transport found in veins. Blood flow was achieved using a magnetic gear pump 
(Benchtop Analog Drive, 0.261 mL/rev) from Cole Parmer (Vernon Hills, IL), setting flow 
rates to 1-4 mL min-1 as measured by a flow meter. To construct the binding curves 
(titrations of aptamer with target), stock solutions of each target molecule were prepared 
fresh prior to measurements in PBS buffer or blood, respectively. Examples of typical 
binding curves are provided (Fig. S5.6).  
 
In vivo Experiments 
Animals. Adult male Sprague-Dawley rats (300-500 g; Charles River Laboratories, 
Wilmington, MA, USA) were pair housed in a temperature and humidity controlled 
vivarium on a 12-h light-dark cycle and provided ad libitum access to food and water. All 
animal procedures were consistent with the guidelines of the NIH Guide for Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use Committee of 
the University of California Santa Barbara.  
Surgery. For the anesthetized preparation, rats were anesthetized using isoflurane gas 
inhalation (2.5%) and monitored throughout the experiment using a pulse oximeter (Nonin 
Medical, Plymouth, MN) to measure heart rate and %SpO2 to insure depth of anesthesia. 
After exposing both ventral jugular veins, a simple catheter made from a SILASTIC tube 
(Dow Corning, Midland, MI, USA) fitted with a steel cannula (Plastics One, Roanoke, VA, 
USA) was implanted into the left jugular vein. 0.1-0.3 mL of heparin (1000U/mL, SAGENT 
Pharmaceuticals, Schaumburg, IL, USA) were immediately infused through the catheter to 
prevent blood clotting. The sensor was inserted into the right jugular vein and secured in 
place with surgical suture. Following drug infusions (see below), animals were euthanized 
by overdose on isoflurane.  
For the awake preparation, rats were anesthetized (as above) and then mounted on a 
stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) with a gas anesthesia 
head holder to maintain anesthesia. After a subcutaneous injection of an analgesic (1mg/kg 
Flunixiject, Henry Schein Animal Health, Dublin, OH, USA), a midline incision was made 
along the dorsal surface of the scalp and a second incision was made on the ventral portion 
of the neck above the jugular vein. Using a similar catheter construction described above, we 
implanted the catheter tube into the right jugular vein and sutured it in place before sealing 
the wound with skin glue. The surface of the skull was then exposed and 4 screws were 
drilled into the bone to provide a platform for the cannula to be cemented to the head. Dental 
cement was applied to the skull surface while the cannula was held in place using the 
stereotaxic arm. After the cement had set, the catheter was flushed with antibiotics (1 mg/kg 
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gentamicin Henry Schein Inc., Dublin, OH, USA and 1 mg/kg cefazolin, WG CriticalCare, 
Paramus, NJ, USA) and the animal was monitored for postoperative recovery before being 
returned to the vivarium colony. Daily monitoring of weight and condition of recovery 
followed for 4 days in which the animal was treated with analgesic (as above) and observed 
for signs of distress/wound inflammation. No further procedures were carried out on these 
animals for a minimum of one week. 
Measurements. A 30 min sensor baseline was established before the first drug infusion. 
For anesthetized animals a 3 mL syringe filled with the target drug was connected to the 
sensor-free catheter (placed in the jugular opposite that in which the sensor is emplaced) and 
placed in a motorized syringe pump (KDS 200, KD Scientific Inc., Holliston, MA, USA). 
After establishing a stable baseline, the target drug was infused through this catheter at a rate 
of 0.2 mL/min. Target drugs included kanamycin (0.1 M solution; homemade), gentamicin 
(10 mg/mL, Henry Schein Inc., Dublin, OH, USA), tobramycin (0.1 M solution; homemade), 
and doxorubicin (1.0 mM, homemade). After drug infusion, recordings were taken for up to 
2 h before the next infusion. The real-time plotting and analysis of voltammetric data were 
carried out with the help of a script written in R Studio. 
For the awake preparation, a pre-catheterized animal was first briefly anesthetized (as 
above). The sensor was threaded down the catheter and tightly attached to it via a homemade 
plastic joint. The joint protects the sensor from being accidentally pulled out by the animal 
while exploring his surroundings. Once implanted, the E-AB sensor was affixed to a leash in 
an operant chamber (Med Associates Inc., Fairfield, VT, USA). The animal was then 
allowed to recover from anesthesia and explore the chamber while recordings proceeded as 
described above. Following the baseline recording, the target drug was introduced via either 
an intramuscular injection (thigh) or via an intravenous injection given through the same 
catheter used to emplace the sensor.  
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VI. A “Clinical Watchdog” for Physiological Proteins: Real-Time in 
vivo Assurance of Subcritical Growth Factor Serum Levels5  
Abstract: 
Hundreds of protein biomarkers and many “biological” (protein therapeutics) are FDA 
approved for the diagnosis, monitoring and treatment of disease. Present techniques to 
monitor the levels of these circulating proteins are cumbersome, laboratory-based 
techniques, which only measure a single timepoint during therapy. In contrast, we describe 
here an implantable electrochemical aptamer-based sensor for the continuous, in vivo 
measurement of circulating platelet-derived growth factor. We use the remarkably stable 
interaction between the sensor and target to assess and optimize signal stability directly in 
the blood stream of a living rat. 
A. Introduction 
The number of disease-diagnostic protein “biomarkers” continues to grow, with a survey 
of FDA approvals for protein-based assays through 2008 alone finding more than 200 unique 
protein targets circulating in plasma or serum [1]. A few of the examples discovered to date 
reporting on heart failure, rheumatic disease, cancers and overactive immune responses [1]. 
Even the routine analysis of these biomarkers, however, remains challenging as existing 
methods for the detection of specific proteins are limited to analyzing individual blood 
draws (i.e., single timepoint “snapshots”) most often via laboratory-based technologies that 
require hours-to-days to return actionable information to healthcare providers [2]. In 
                                                 
5 This chapter in preparation for publication (with Chapter IV) as J. Somerson, N. 
Arroyo-Currás, G. Ortega, K. Ploense, H. Li, T. Kippin and K.W. Plaxco, “Nanomolar in 
vivo and calibration-free in vitro measurement of a circulating protein”. 
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contrast, were a technology available that could support the high-frequency measurement of 
such biomarkers in real-time and in situ in the living body it would be possible to 
continuously monitor many critical health states.  
Real-time protein monitoring can provide a valuable tool for diagnosing diseases, 
observing disease progression and response to therapy and monitoring when spikes in 
circulating proteins might indicate dangerous events. For example, a massive upregulation of 
proinflammatory cytokines in response to an immune event (a “cytokine storm”) can cause 
harmful and even fatal inflammation [7–9]. An acute myocardial infarction is often 
accompanied by a large increases in plasma levels of the cardiac troponins; elevation of 
circulating cardiac troponin above the 99th percentile is sufficient for diagnosis of acute 
myocardial infarction [10]. Circulating proteins also provide diagnostic and prognostic 
information in the diagnosis and treatment of multiple cancers [3–6]. Current approaches to 
measuring such markers, however, are all single-time-point laboratory-based assays or 
qualitative, point-of-care dipsticks. The availability of a technology that, in contrast, 
provides real-time quantitative information regarding the levels of these biomarkers could 
provide valuable rapid diagnostic feedback and could even serve to provide timely, early 
warning alerts upon diagnostically relevant concentration spikes.  
Motivated by the value to be added by platforms capable of continuously monitoring the 
levels of specific biomarkers in situ in the body, we aim to expand the in vivo success of 
electrochemical aptamer-based sensors to the larger challenge of in vivo protein 
measurement. Electrochemical aptamer-based sensors (E-AB sensors) couple the specificity 
of precise biological recognition with the quantitative and selective readout of 
electrochemical measurement. These sensors use aptamers, short nucleic acid strands 
selected in vitro to sensitively and specifically bind an arbitrary target of interest [11]. E-AB 
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sensors bind these aptamers to an electrode surface and append an electrochemically-active 
tag distal from the electrode. Binding of the target to the aptamer changes the conformation 
of the sensor molecule, creating a quantitative change in electrode signal linked to the 
concentration of target present [12]. Critically, because the electrochemical signal is limited 
to a narrow potential window, there are very few electrochemically-active interfering 
species, enabling the deployment of these sensors into complex media, such as blood serum 
[13,14], and even in vivo into living systems [15] where they continue to provide 
quantitative, continuous measurement of an analyte of choice. For example, we have 
previously used E-AB sensors to perform the real-time monitoring of several small molecule 
drugs in situ in the bodies of awake, freely-moving rats [15]. Here, we use the previously-
described E-AB sensor against the BB isoform of the human platelet-derived growth factor 
[16]. This sensor consists of an aptamer against this protein bound through a thiol linker on 
its 5’ end to an electrode surface and displaying a methylene blue electrochemical tag on its 
3’ end (Fig. 6.1). Using this sensor, here we describe the first use of an E-AB sensor to 
monitor rising levels of a protein biomarker directly in the bloodstream of a living animal. 
Monitoring protein targets in-vivo provides new challenges relative to our past work 
with the E-AB platform, which, for in-vivo studies, had focused entirely on the detection of 
small-molecule drugs. First, the concentrations of typical protein biomarkers in blood are 
much lower than the clinically relevant concentrations of small molecule drugs – tens of 
nanomolar as opposed to the tens-to-hundreds of micromolar [15]. Protein targets can also 
confound anti-fouling techniques, which rely on interfering with the approach of blood 
proteins to the electrode surfaces. Previous work with E-AB sensors either in vivo or 
immediately ex vivo have used microdialysis membranes [15] and buffer diffusion layers 
[17] to help to reduce the drift associated with fouling of the electrode surfaces. For this 
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study, it is essential to allow protein to diffuse to the sensor surface and so this proves a 
more rigorous study of in vivo sensor stability. An additional challenge for protein-detecting 
sensors is the extremely slow off-rates associated with dissociation of these targets from 
their aptamer receptors. The PDGF sensor, for example, which is the test bed I employed in 
these studies, exhibits stable signal for hours even after the protein target is completely 
removed from the measured solution (Fig. 6.2). While this is a challenge for real-time 
measurement, we can still find great value as a clinical sensor and as a way to improve our 
sensor platform. Specifically many biomarker targets cause concern when their levels rapidly 
rise, as in the example of cytokine storms [8]. While real-time knowledge of absolute serum 
concentration would be of value, the understanding that a spike in protein concentration has 
happened or continues to occur provides the most important diagnostic information.  
Beyond the clinical utility of an implantable device to continuously monitor for protein 
concentration spikes, this tightly-binding sensor can also provide valuable information 
towards improving the E-AB sensor platform. Specifically , this signal stability proves an 
excellent opportunity to examine the noise observed within in vivo measurements and 
deconvolute the noise inherent to our sensor system from the physical noise exhibited in the 
metabolism of the target. Because we know that this signal should remain stable for hours 
after a spike in protein concentration, we can use this system to more rigorously compare the 
stability and reproducibility of multiple drift-correction strategies. In this work, we compare 
two previously-described drift-correction strategies and describe for the first time a new 
drift-correction strategy that uses the inherent biomolecular kinetics of our sensor molecule 
to create self-correcting signals. 
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Figure 6.1. (A) Binding of the protein target to an electrochemical aptamer-based (E-AB) 
sensor alters the conformation of the electrode-bound aptamer, changing the accessibility of 
an attached methylene blue redox reporter (blue circle). This, in turn, results in a change in 
electron transfer kinetics. Monitoring electron transfer kinetics using square wave 
voltammetry, we see a quantitative change in peak current in response to target binding. By 
changing the frequency of the square wave measurement (i.e., changing the timescale of the 
measurement) we can obtain either (B) “signal-on” responses (here at high frequencies), in 
which peak current increases in the presence of target, (C) “signal-off” response (here at low 
frequencies, in which the peak current decreases in the presence of target, or (D) 
nonresponsive behavior (at intermediate frequencies), in which the peak current does not 
change in the presence of target. Using these alternative behaviors we have developed a 
number of means of providing drift correction to the E-AB platform. 
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B. Results and Discussion 
 
Figure 6.2. The PDGF E-AB sensor rapidly responds to increasing target concentration (first 
gray line). In contrast, its re-equilibration after the removal of target (second gray line) is 
very slow. Shown are the average signal change (dark trace) and standard error (light trace) 
for seven replicate electrodes in flowing buffer. The standard error for the 10 Hz 
measurement is obscured by the data.  
 
We used the stability of the PDGF sensor signal to compare two previously-reported 
methods of drift correction and one new technique. The first, kinetic differential 
measurement (KDM), was first described by Ferguson et al. [17]. The second, calibration-
free measurement, was first described by Li et al. [18]. And the third, ratiometric 
measurement, is describe d here for the first time. Each of these techniques relies on 
exploiting the kinetic sensitivity of square wave measurements to obtain “signal-on” 
measurements and either “signal-off” or nonresponsive measurements from the same 
population of bound sensor molecules [19]. We compare the relative stability of each of 
these calculations directly in vivo in the same animals (Fig. 6.5) and the reproducibility of 
these measurements between three rats given the same injected dosage (Fig. 6.6).  
Kinetic differential measurement relies on subtractive drift correction (Fig. 6.3). That is, 
this approach employs a pair frequencies that differ in signal gain upon target binding but 
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drift in unison. Here I have employed a signal-on frequency (300 Hz) and a nonresponsive 
frequency (40 Hz), which both drift in concert when the sensor is deployed in vivo in the 
jugular of a live rat (Fig. 6.3A). KDM calculations, rather than using the raw measured 
electrochemical currents, normalize measured current to an observed baseline and use this 
normalized, proportional signal change (Fig. 6.3B). KDM takes the difference between these 
normalized responses to reduce signal drift (Fig. 6.3C). Using the standard Langmuir 
isotherm relationship between KDM-corrected signal and protein concentration allows for 
the calculation of protein concentrations (Fig. 6.3D). 
 
Figure 6.3. KDM uses subtractive correction to correct signal drift. (A) The raw in vivo 
current drifts, but signal persists. We use 300 Hz as a signal-on frequency and 40 Hz as a 
nonresponsive frequency. (B) KDM normalizes each of these frequencies to “signal change” 
– the proportion of the current to initial current. (C) Subtracting these two frequencies that 
drift in concert creates a flatter, more stable signal (KDM). (D) We use the previously 
measured relationship between KDM signal change and protein concentration to calculate 
the in vivo concentration of PDGF. 
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In contrast to KDM, which is a differential measurement, ratiometric and calibration-free 
measurements use the ratios of signaling currents to reduce drift (Fig. 6.4). Calibration-free 
measurement, explained in more detail in Chapter IV, uses a training set of sensors to find a 
global fit for three constants: the ratio between the signal-on current in the absence of target 
and the nonresponsive current (α), the ratio between the saturated signal-on current and the 
signal-on current in the absence of target (γ) and the standard binding constant KD (Fig. 
6.4C). Calibration-free measurement uses the relationship between the measured currents 
and these previously obtained constants to calculate protein concentrations (Fig. 6.4D). 
Ratiometric measurement calculates the concentration similarly, but with the new 
understanding that α, the ratio between the signal-on current in the absence of target and the 
nonresponsive current, varies from one in-vivo placement to the next. Ratiometric 
measurement uses similar ratiometric calculations of the raw observed currents (Fig. 6.4B) 
but instead of using a previously calculated baseline current ratio (α), ratiometric 
measurement uses the observed ratio between the initial currents at the time of measurement 
to create a more realistic baseline. Using this ratio instead of the pre-determined ratio 
provides accurate in-vivo concentrations (Fig. 6.4D). 
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Figure 6.4. Calibration-free and ratiometric measurements are calculated from the ratio of 
signals obtained at a signal-on frequency (here 300 Hz) and a nonresponsive frequency (here 
40 Hz). (A) Raw currents exhibit signal drift over the course of an in vivo experiment. (B) 
The ratio between these two currents (black) corrects some of the exhibited drifts. (C) The 
previously measured relationship between the signal-on and nonresponsive frequency and 
the concentration of PDGF produce constants α, the ratio between baseline signal-on current 
and nonresponsive current, γ, the ratio between baseline signal-on current and saturated 
signal-on current and KD, the binding constant of these sensors. (D) Calibration-free 
measurements (green) use the constants measured previously to calculate an expected 
concentration from these in vivo measurements. Ratiometric measurements (orange) use the 
gain (γ) and the binding constant (KD) to calculate an observed concentration but use the 
observed ratio between the measurement frequencies as a baseline rather than the previously 
measured constants.  
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Figure 6.5. Spiking in-vivo PDGF levels are easily identified. Shown are data from four 
different rats, three rats (A-C) have one intravenous injection of 0.5 mg/kg PDGF and one 
rat (D) has two injections – one injection of 0.2 mg/kg PDGF followed by another of 0.5 
mg/kg PDGF, showing our ability to measure increasing doses. Three different calculated 
concentrations from the same sensor are shown: KDM-calculated concentrations (light blue), 
calibration-free-calculated concentrations (green) and ratiometric-calculated concentrations 
(orange).  
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Figure 6.6. When comparing rat-to-rat in vivo measurement variation by calculation 
technique, we find reasonable agreement between KDM-calculated measurements and 
ratiometric-calculated measurements. Each color represents an individual rat, all are given 
the same dose of PDGF (0.5 mg/kg intravenous injection). The ratiometric-calculated 
concentrations seem to be the most stable of the three techniques. 
 
When comparing these three measurement techniques, we find the most stable and 
reproducible signal using ratiometric data processing (Fig. 6.6C). While calibration-free 
measurements still have significant utility for ex vivo measurements, the vasculature of a 
living animal seems to be too variable to use the same constants for each animal (Fig. 6.6A). 
KDM measurements prove to be fairly stable and reproducible (Fig. 6.6B), though they are 
not as stable or reproducible as ratiometric measurements. KDM measurements also prove 
more variable towards higher concentrations, where a smaller current variation results in a 
large variation in measured concentrations (Fig. 6.5D). 
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In this work, we show sensitive, continuous measurement of a protein target directly in 
the bloodstream of living animals for the first time (Fig. 6.5), even observing a quantitative 
difference between injections of different doses in the same animal (Fig. 6.5D). We 
quantitatively measure nanomolar blood concentrations, making these the most sensitive E-
AB in vivo measurements to date.  
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Figure S6.1. Membrane-protected electrodes exhibit signal response within error of zero 
signal change when challenged with target. Data shown are the mean and standard error of 4 
electrodes in flowing whole blood, with KDM using the subtractive difference between 120 
Hz and 10 Hz measurements.  
 
C. Materials and methods. 
Human recombinant Platelet-derived Growth Factor-BB (expressed in E. coli) was 
purchased from Prospec-Tany Technogene Ltd. (Ness Ziona, Israel) and used as received 
without further purification. PDGF-BB was dissolved in water to a concentration of 10.3 µM 
(250 µg/mL) then further diluted for titration in the same media as measurements were 
performed. 20X phosphate-buffered saline (PBS) was purchased from Sigma Aldrich (St. 
Louis, MO), diluted to 1X concentration and pH corrected to 7.4 using sodium hydroxide 
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and hydrochloric acid. Whole bovine blood and bovine plasma were purchased from 
HemoStat Laboratories (Dixon, CA). Blood was shipped with 3 IU/mL sodium heparin and 
used within a week of receipt. Gold wire was purchased from A-M Systems (Sequim, WA). 
Heat-shrink PTFE was purchased from Zeus Labs (Branchburg Township, CA). 
Polyethersulfone membranes (P/N: C02-E20U-05-N) were purchased as MicroKros Filter 
Modules from Spectrum Laboratories (Rancho Dominguez, CA). The filter modules were 
cut open and the hollow membranes were extracted from them. Oligonucleotides were 
synthesized by Biosearch Technologies (Novato, CA) and purified by dual HPLC. 6-
mercapto-1-hexanol and tris(2-carboxyethyl)phosphine were purchased from Sigma Aldrich 
(St. Louis, MO) and used as received. 
Catheters (18G) and 1 mL syringes were purchased from Becton Dickinson (Franklin 
Lakes, NJ). Silver wire (200 µm diameter) was purchased from Alfa Aesar (Ward Hill, MA); 
to employ this as a reference electrode it was immersed in bleach overnight to form a silver 
chloride film. Insulated pure gold and silver wires (100 µm diameter) were purchased from 
A-M systems. Heat-shrink polytetrafluoroethylene insulation (PTFE, HS Sub-Lite-Wall, 
0.02, 0.005, 0.003±0.001 in, black-opaque, Lot # 17747112-3) was purchased from ZEUS 
(Branchburg Township, CA). 
 
PDGF-BB aptamer sequence. 
5’ – 6-carbon thiol linker – CAGGC TACGG CACGT AGAGC ATCAC CATGA 
TCCTG – methylene blue redox tag – 3’ 
Sensor fabrication and preparation. 
  102 
Segments of gold wire were cut to 7 cm in length to make sensors. These wires were 
then insulated by applying heat to shrinkable tubing around the body of the wires. The sensor 
window (i.e., the region without insulation) was approximately 5-8 mm in length. To 
increase surface area of these working electrodes (to obtain larger peak currents) the sensor 
surface was roughened electrochemically via immersion in 0.5 M sulfuric acid followed by 
jumping between Einitial = 0.0 V to Ehigh = 2.0 V vs Ag/AgCl, back and forth, for 100,000 
pulses. Each pulse was of 2 ms duration with no “quiet time.”  
To fabricate sensors an aliquot of the PDGF aptamer was thawed and then reduced for 1 
h at room temperature with a 1000-fold molar excess of tris(2-carboxyethyl)phosphine. A 
freshly roughened gold electrode was then rinsed in di-ionized water before being immersed 
in a solution of the appropriate reduced DNA construct at 200 nM in 1X PBS for 1 h at room 
temperature. The sensors were immersed overnight at 4°C for 12 h in 20 mM 6-mercapto-1-
hexanol in 1X PBS to coat the remaining gold surface and remove nonspecifically adsorbed 
DNA. After this the sensors were rinsed with di-ionized water and stored in PBS.  
 
Electrochemical measurements. 
Electrochemical measurements were performed at room temperature using a handheld 
potentiostat (Model 1242 B, CH Instruments, Austin, TX) using a 2-electrode setup in which 
the reference and counter electrodes were a silver wire coated with a silver chloride film as 
described above. Square wave voltammetry was performed at 300 Hz using a potential step 
of 0.001 V, 10 Hz using a potential step of 0.004 V and at 40 Hz using a potential step of 
0.001 V, all using an amplitude of 0.025 V. 
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In vivo Experiments 
Animals. Adult male Sprague-Dawley rats (300-500 g; Charles River Laboratories, 
Wilmington, MA, USA) were pair housed in a temperature and humidity controlled 
vivarium on a 12-h light-dark cycle and provided ad libitum access to food and water. All 
animal procedures were consistent with the guidelines of the NIH Guide for Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use Committee of 
the University of California Santa Barbara.  
Surgery. For the anesthetized preparation, rats were anesthetized using isoflurane gas 
inhalation (2.5%) and monitored throughout the experiment using a pulse oximeter (Nonin 
Medical, Plymouth, MN) to measure heart rate and %SpO2 to insure depth of anesthesia. 
After exposing both ventral jugular veins, a simple catheter made from a SILASTIC tube 
(Dow Corning, Midland, MI, USA) fitted with a steel cannula (Plastics One, Roanoke, VA, 
USA) was implanted into the left jugular vein. 0.1-0.3 mL of heparin (1000U/mL, SAGENT 
Pharmaceuticals, Schaumburg, IL, USA) were immediately infused through the catheter to 
prevent blood clotting. The sensor was inserted into the right jugular vein and secured in 
place with surgical suture. Following drug infusions (see below), animals were euthanized 
by overdose on isoflurane.  
 
Measurements. A 30 min sensor baseline was established before the first drug infusion. 
A 3 mL syringe filled with the target drug was connected to the sensor-free catheter (placed 
in the jugular opposite that in which the sensor is emplaced) and placed in a motorized 
syringe pump (KDS 200, KD Scientific Inc., Holliston, MA, USA). After establishing a 
stable baseline, the PDGF-BB protein was infused through this catheter at a rate of 0.2 
mL/min.  
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